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Abstract 
 
Natural Killer (NK) cells are effective at targeting malignant cells without being 
direct effectors of graft-versus-host disease. NK cell immunotherapy has been shown 
to be safe in the clinic however efficacy has been inconsistent. We have previously 
shown that NK cells can be produced in large quantities from frozen cord blood (CB) 
CD34+ cells. We hypothesised that producing NK cells with optimum activation 
status that can proliferate and persist in vivo is fundamental for the development of a 
clinically relevant cellular product. Here, we assess if the cells can further respond to 
additional cytokine stimulation and if function is maintained post cryopreservation. 
Further, we consider how cell cytotoxicity compares to peripheral blood (PB) NK 
cells and CBNK cells against patient acute myeloid leukaemia (AML) blasts and 
solid tumours and which activation method is superior.  
  
We found that the differentiated NK cells could respond to interleukin-2 and 
proliferate in vitro and that their function was unaffected by cryopreservation. The 
differentiated NK cells could kill leukaemic cells and more importantly could persist 
for longer and in higher numbers in vivo over other sources of NK cells. Priming the 
cells consistently led to higher levels of killing of patient leukaemic blasts and solid 
tumour cell lines in vitro, however this activation step was not required to observe 
killing of patient AML blasts in vivo. This implies that the cells might not require 
prior activation before infusion resulting in a more economical cellular therapy that 
is more easily translatable to the clinic. 
 
We are therefore able to generate and cryopreserve NK cells differentiated from CB 
CD34+ cells in high numbers allowing for multiple infusions of highly cytotoxic NK 
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cells that have potential to further proliferate in vivo and have a clear survival 
advantage over other sources of NK cells.  
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1.1. The immune system 
 
The human immune system is a dynamic collection of cells, tissues and molecules 
that work together to protect us from the damaging effects of pathogens, toxins and 
cancer. The immune system can be sub-divided into two categories, innate immunity 
and adaptive immunity. 
 
1.1.1. The innate immune system 
 
The innate immune system is the first line of defence against pathogens and is 
continuously active and ready to mobilise an immune response. The main 
components of the innate immune system are epithelial barriers, phagocytic 
leukocytes, dendritic cells (DCs), natural killers (NK) cells, circulating plasma 
proteins and cytokines. NK cells being the focus of this thesis they will be described 
in more details later on in the introduction. The innate immune system works in a 
non-specific manner without any memory and can discriminate between self and 
non-self via pattern recognition receptors (PRR). After penetration of epithelial 
barriers innate immune cells are able to identify self-transformation induced by 
pathogens or infection. The action of the innate immune system is rapid and 
elimination is often achieved within hours. If pathogens are able to evade the innate 
immune response the adaptive immune system is called into action. 
 
1.1.2. The adaptive immune system 
 
The adaptive immune system is made up of two types, humoral immunity, facilitated 
by antibodies produced by B lymphocytes and cell-mediated immunity controlled by 
T lymphocytes. This system is based on its ability to recognise, eliminate and have a 
memory of invading pathogens. Immunological memory refers to the capacity of the 
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immune system to respond more rapidly and effectively to a pathogen that has been 
encountered previously. Therefore if the same pathogen were to re-infect the body 
memory cells are able to mount a rapid and powerful response without the host 
observing further infection. Although NK cells are considered members of the innate 
immune system they have been shown to possess traits of adaptive immunity and can 
acquire immunological memory in a method similar to that of T and B cells 
(O'Sullivan et al., 2015).  
 
1.1.3. Humoral immunity 
 
B cells release antibodies that mediate the humoral immune response. Antibodies are 
glycoproteins that consist of two identical polypeptides known as the heavy chains 
and two shorter identical polypeptides known as the light chains. There are 5 
different types of antibodies; IgA, IgD, IgE, IgG and IgM. Each are classified 
according to their heavy chain type and have a different function and distribution 
within the human body. Antibodies mediate a variety of functions such as 
extracellular microbe neutralisation, activation of the complement system and 
identification of target cells to be eliminated by antibody-dependent cell-mediated 
cytotoxicity (ADCC). B cells are capable of acting as antigen presenting cells 
(APCs) to T cells where T cell receptors (TCRs) on T helper (TH) cells bind to the 
major histocompatibility complex (MHC) class II / antigen complex on B cells 
resulting in T cell activation and the release of a secondary activating signal to B 
cells. The humoral immune response generates specific high affinity antibodies 
against antigens and long-lived secreting cells with specific memory capable of 
responding rapidly to subsequent antigen exposure (Abbas et al., 2012). 
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1.1.4. Cell mediated immunity 
 
The facilitators of cell-mediated immunity are T cells. T cells are classified into 
CD4+ TH cells and CD8
+ cytotoxic T cells (CTLs) (Abbas et al., 2012). T cell 
responses are dependent on recognition of cell-associated antigens resulting in the 
expansion of antigen specific clones and differentiation of effector and memory cells 
(Abbas and Lichtman, 2009). 
 
T cells express a TCR that is a molecule restricted to recognition of peptides bound 
to MHC molecules on APCs. MHC molecules are polymorphic and are divided into 
MHC class I expressed by all nucleated cells and MHC class II expressed by DCs, 
macrophages and B cells. A peptide binding cleft on the outer surface of both classes 
of MHC molecules allows the presentation of antigens to T cells. CD8+ CTLs 
recognise peptides presented by MHC class I molecules and CD4+ TH cells recognise 
peptides presented by MHC class II molecules (Parkin and Cohen, 2001). Following 
antigen recognition CD8+ CTLs expand and eliminate infected or cancerous cells. 
Antigen-specific T cells proliferate and undergo clonal expansion within 2 days of 
antigen exposure. Post antigen clearance, a small pool of T cells survives that 
differentiate into long-lived memory T cells. They remain quiescent but have a rapid 
response after subsequent exposure to the same antigen. Two forms of memory T 
cells are produced. Effector memory T cells (TEM) express chemokine receptors 
involved in homing to inflamed tissues such as CCR4, CCR5 and CXCR3 and are 
involved in the immediate effector function post antigen re-stimulation. Central 
memory T cells (TCM) on the other hand express CCR7, L-selectin and CD45RO and 
reside in the lymphoid organs. TCM form the reactive memory and readily undergo 
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clonal differentiation and expansion into effector cells in response to secondary 
antigen exposure (Sallusto et al., 2004). 
 
Peptide presentation to naïve CD4+ TH cells results in the differentiation of 
specialised TH 1 or TH 2 cells required for the response to intracellular and 
extracellular microbes (Mosmann and Sad, 1996), TH 17 cells that secrete IL-17, a 
pro inflammatory cytokine (Ouyang et al., 2008). Regulatory T cells are another 
subset of CD4+ T cells that maintain tolerance to self antigens and prevent 
autoimmune disease (Yamaguchi and Sakaguchi, 2006).  
 
1.2. Natural killer cells 
 
Human NK cells were discovered in 1975 when spontaneous lysis of mouse tumour 
cells was observed without prior stimulation (Kiessling et al., 1975a, Kiessling et al., 
1975b, Herberman et al., 1975b, Herberman et al., 1975a). Human NK cells make up 
around 15 % of all circulating lymphocytes and are characterised by their surface 
expression of CD56 and CD16 and absence of CD3 (Lanier et al., 1989, Ritz et al., 
1988) NK cells have been found to populate the peripheral blood (PB), gut, liver, 
lungs, lymph nodes, thymus and uterus (Carrega and Ferlazzo, 2012). 
 
NK cells are members of the innate immune system capable of mediating an immune 
response against viruses, parasites, bacteria and tumour cells (Moretta et al., 2002a, 
Raulet, 2004). Unlike T and B cells, NK cell effector function can be achieved 
without prior exposure to an antigen or somatic rearrangement of their surface 
receptors, instead NK cells are able to discriminate between healthy and target cells 
by detecting missing self on target cells by a phenomenon known as the “missing self 
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hypothesis”. This concept was first proposed in 1986 when Karre and colleagues 
identified that the loss of self-MHC expression by murine lymphoma cells triggered 
NK cell effector function (Karre et al., 1986). It was deduced that NK cell inhibition 
was achieved after engagement of self-MHC molecules with inhibitory receptors 
such as killer Ig-like receptors (KIRs) and CD94/NKG2A in humans and Ly49 
receptors in mice. Therefore if a cell down-regulated MHC expression it would then 
be a target of NK cell cytotoxicity.  
 
1.3. Natural killer cell subsets  
 
Human NK cells can be subdivided into two key subsets via their intensity of CD56 
expression: CD56bright and CD56dim that have distinct function and distribution 
(Lanier et al., 1986).  
 
1.3.1. CD56bright natural killer cells 
 
CD56bright NK cells comprise 10 % of total circulating NK cells but constitute the 
majority of NK cells found in secondary lymphoid tissues; they are the predominant 
source of NK cell immunoregulatory cytokines (Cooper, 2001, Jacobs et al., 2001). 
CD56bright NK cells express low levels of CD16 (Cooper et al., 2001) and KIR 
(Andre et al., 2000) but have a high expression of the lectin-like inhibitory receptor 
CD94/NKG2A (Voss et al., 1998), L-selectin, CCR7 and CXCR3, receptors 
associated with homing to the lymph node (LN) (Campbell and Colonna, 2001). 
CD56bright NK cells play an essential role in recruiting and activating other immune 
cells by releasing a variety of cytokines including interferon gamma (IFN-), tumour 
necrosis factor alpha (TNF-), lymphotoxin alpha (TNF-), interleukin-10 (IL-10), 
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interleukin-13 (IL-13) and granulocyte-macrophage colony-stimulating factor (GM-
CSF). Further, CD56bright NK cells express the high affinity IL-2 receptor complex 
(Caligiuri et al., 1990) resulting in higher responsiveness to low dose IL-2 and 
improved proliferative capacity in comparison to CD56dim NK cells. A diagram of a 
CD56bright PBNK cell and its associated receptors can be seen in figure 1.1. 
 
 
Figure 1.1. CD56bright PBNK cells. CD56bright PBNK cells are potent producers of 
pro-inflammatory cytokines and express L-selectin, CCR7, high CD94/NKG2A but 
lack KIRs. 
 
1.3.2. CD56dim natural killer cells 
 
CD56dim NK cells are the more abundant cell subset, making up 90 % of circulating 
lymphocytes and are considered to be cytolytic and efficient effectors of ADCC 
(Campbell and Colonna, 2001, Cooper et al., 2001, Jacobs et al., 2001). CD56dim NK 
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cells express CD16, KIRs and possess high levels of perforin and granzymes (Jacobs 
et al., 2001). They are enriched in the bone marrow (BM), blood and spleen 
(Fehniger et al., 2003, Freud et al., 2006). Additionally following target cell 
recognition CD56dim NK cells have been shown to be capable of secreting low levels 
of inflammatory cytokines such as IFN- (Fauriat et al., 2010, Juelke et al., 2009). In 
contrast to CD56bright NK cells, CD56dim NK cells express the intermediate-affinity 
IL-2 receptor and proliferate weakly in response to high dose IL-2 in vitro (Baume et 
al., 1992). A diagram of a CD56dim PBNK cell and its associated receptors can be 
seen in figure 1.2. 
 
 
Figure 1.2. CD56dim PBNK cells. CD56dim PBNK cells mediate cytotoxic function 
and have a high expression of CD16. They lack CCR7 and L-selectin but express 
CXCR1 and CX3CR1.  
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1.4. Natural killer cell development 
1.4.1. Lymphocytes 
 
Haematopoetic stem cells (HSCs) in the BM differentiate into the cellular 
components of the blood via a process known as haematopoiesis. HSCs first divide 
into myeloid and lymphoid progenitors. The myeloid lineage develops into 
neutrophils, eosinophils, basophils, monocytes, masts cells and DCs (Edvardsson et 
al., 2006) whereas the lymphoid lineage gives rise to B, T and NK cells (Rolink et 
al., 2006). A majority of immune cells complete their maturation in the BM whereas 
other will migrate to other tissues.  
 
1.4.2. NK cells 
 
NK cell differentiation and development occurs primarily in the BM as identified by 
selective BM ablation studies in mice in the 1970’s (Kumar et al., 1979, Seaman et 
al., 1978). Other areas of NK cell development have since been identified such as 
thymus-derived NK cells characterised by CD127 and GATA-3 expression 
(Vosshenrich et al., 2006), a CD56bright population derived from CD34dimCD45+ cells 
found in the LNs (Freud et al., 2006) and the ability of CD34+ cells present in the 
human decidua to give rise to functional NK cells involved in tissue remodelling and 
immunomodulation (Vacca et al., 2011). These represent a distinct lineage of NK 
cells at a low percentage of the total population; the general consensus is that a 
majority of NK cells differentiate from CD34+ cells in the BM in several different 
maturation states (Freud and Caligiuri, 2006). Tissue specific NK cells are discussed 
in further detail later on in the chapter. 
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Studies in mice have identified 6 stages of NK cell development as well as 
identifying an elusive transition of cell development from common lymphoid 
progenitor (CLP) to NK progenitor (NKP) (Carotta et al., 2011). Phenotypic 
differences however between human and mouse NK cells means this data cannot be 
directly correlated.  
 
In current models human NK cell development occurs in defined stages suggesting 
that CLPs differentiated from HSC CD34+ cells can give rise to a NKPs followed by 
immature NK (iNK) cells and then mature NK (mNK) cells (Huntington et al., 
2007). A population of CLPs characterised as Lin-CD34+CD38+CD10+ has been 
described to give rise to B, T and NK cells but not other  cells of the myeloid lineage 
(Galy et al., 1995).  
 
Commitment to the NK cell lineage is dependent on the acquisition of IL-2/IL-15R 
and IL-2/IL-15R rendering the NKPs responsive to IL-15, the cytokine that drives 
NK cell differentiation (Colucci et al., 2003). NKPs responsive to IL-15 differentiate 
into the NK/T progenitor that can then be identified by the expression of CD117 and 
lack of CD10 expression. The next stage is the commitment of lymphoid cells to the 
NK cell lineage that is coupled with the acquisition of CD56 (Freud and Caligiuri, 
2006). Further CD56bright NK cells are thought to be precursors of CD56dim NK cells 
as they have been shown to be more abundant in the blood following haematopoietic 
stem cell transplantation (HSCT) (Shilling et al., 2003) have longer telomeres 
(Romagnani et al., 2007) and differentiate into CD56dim NK cells in humanised 
mouse models (Huntington et al., 2009). Continued differentiation of CD56dim NK 
26 
 
cells is accompanied with the loss of NKG2A and CD62L, the increased acquirement 
of KIRs and CD57 and a reduced proliferative capacity (Bjorkstrom et al., 2010).  
 
The complete model of NK cell development proposed by Freud and Caliguiri can be 
seen in figure 1.3. Here the first stage (pro-NK) of differentiation is identified by the 
expression of CD34, CD45RA and CD10 and absence of CD122 indicating a lack of 
response to IL-15. Stage 2 (pre-NK) sees the downregulation of CD10 and 
expression of CD117 and CD122 enabling IL-15 responsiveness, lineage plasticity is 
still present and pre-NK cells are still capable of differentiation into other lineages. 
Stage 2 NK cells differentiate into stage 3 (iNK) cells that are now committed to the 
NK cell lineage and express CD56, CD161, NKp44 and 2B4. Stage 4 (CD56bright NK 
cells) is marked by the acquisition of CD94 and other NK cell receptors such as 
NKG2D, NKp46 and the loss of CD117. Finally stage 5 (CD56dim NK cells) marks 
the terminal step of NK cell differentiation with the acquisition of CD16 and 
increased KIR expression (Freud and Caligiuri, 2006). A diagram of the stages of 
NK cell development as defined by Freud and Caligiuri in 2006 can be seen in figure 
1.3.  
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Figure 1.3. NK cell development stages as defined by Freud and Caligiuri. NK 
cell differentiation from CD34+ HSCs occurs via distinct developmental stages. 
Stages 1-3 result in commitment to the NK lineage and stages 4 and 5 define 
functional maturation (Freud and Caligiuri, 2006). 
 
1.5. Natural killer cell education 
 
NK cells undergo a final step of maturation known as NK cell licensing or education. 
It has been suggested that this process occurs to allow the cells to become fully 
functional and capable of distinguishing between “self” and “non-self”.  
 
1.5.1. Licensing 
 
It was first demonstrated in mice that NK cells expressing self-inhibitory receptors 
produced more IFN-, this concept is known as NK cell licensing and proved NK 
cell impairment was detected in MHC class I deficient hosts (Kim et al., 2005). 
Licensed NK cells are therefore inhibited by self-MHC class I preventing them from 
attacking healthy cells; in line with this hypothesis unlicensed NK cells are hypo-
functional. Confirming this theory completely in humans has been difficult. It has 
been shown that human NK cells lacking the expression of self-inhibitory receptors 
(KIRs or NKG2A) were hypo responsive (Kim et al., 2008) whereas others found 
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that NK cells with self-specific inhibitory receptors were fully functional (Anfossi et 
al., 2006) (Figure 1.4).  
  
Figure 1.4. Licensing model. The licensing model states that NK licensing requires 
positive engagement of inhibitory receptors with MHC class I on educating cells. 
The lack of this interaction results in cellular hyporesponsiveness (Hoglund and 
Brodin, 2010). License obtained from Nature Publishing Group; 4024850254662. 
 
1.5.2. Arming/Disarming 
 
The absence of expression of self-inhibitory receptors on NK cells in mice led to the 
development of a new concept known as disarming (Fernandez et al., 2005). In this 
concept engagement of inhibitory receptors with MHC class I is a requirement for 
the induction of functionally mature NK cells. Thus NK cell function is dependent on 
MHC class I interaction, cells that fail to interact with MHC class I during 
maturation are “un-armed” and do not attack MHC class I negative targets. On the 
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other hand, in the disarming model NK cells (figure 1.5) are always activated and it 
is the expression of inhibitory receptors that prevent the cells from becoming 
hyporesponsive (Raulet and Vance, 2006). The lack of expression of inhibitory 
receptors for self-MHC and prolonged activation therefore results in hyporesponsive 
NK cells.  
 
Figure 1.5. Disarming model. The disarming model states that NK cell disarming is 
the result of the lack of inhibitory receptor expression that in turn causes persistent 
NK cell stimulation leading to hyporesponsiveness (Hoglund and Brodin, 2010). 
Licensed obtained from Nature Publishing Group; 4024850254662. 
 
1.5.3. Cis-interaction model 
 
Another model of education is that MHC class I molecules interact with inhibitory 
molecules on the same cell in a cis-interaction manner. The hypothesis is that some 
inhibitory receptors deliver an inhibitory signal in the absence of its ligand and that 
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unengaged inhibitory receptors accumulate at the immunological synapse thus 
restricting interaction with target cells (Chalifour et al., 2009). Therefore an NK cell 
expressing both MHC class-I and an inhibitory receptor is responsive and an NK cell 
expressing only an inhibitory receptor is hyporesponsive (figure 1.6). 
 
Figure 1.6. Cis-interaction model. The cis-interaction model states that a cis-
interaction between inhibitory and MHC class I molecules on the same cell results in 
an inhibitory signal at the immunological synapse (Hoglund and Brodin, 2010). 
Licensed obtained from Nature Publishing Group; 4024850254662. 
 
1.5.4. Rheostat model 
 
The rheostat models hypothesises that NK cell reactivity is finely tuned by the 
number of self-MHC class I inhibitory receptors expressed and the affinity for its 
receptor (Brodin et al., 2009, Raulet and Vance, 2006). NK cells that express two or 
more inhibitory receptors for self-MHC class I or those with a higher affinity 
respond more frequently and produce a stronger effector function than NK cells with 
only one inhibitory receptor or those with a lower affinity (Joncker et al., 2009, 
Jonsson et al., 2010). NK cell education is therefore a quantitative process 
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determined by the frequency and strength of engagement of inhibitory receptors with 
self-MHC class I (figure 1.7). 
 
 
Figure 1.7. Rheostat model. The rheostat model states that the strength of NK cell 
responsiveness depends on the strength of the inhibition signal delivered by the 
inhibitory receptors (Hoglund and Brodin, 2010). Licensed obtained from Nature 
Publishing Group; 4024850254662. 
 
1.6. Natural killer cell receptors 
 
NK cell effector function can be triggered by the down regulation of MHC class I or 
up regulation of stress signals by a target cell. A balance of signals delivered by 
inhibitory and activating receptors tightly regulates NK cell functions. 
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1.6.1. Activating receptors 
 
It was previously thought that NK cell activation was the result of MHC class I 
downregulation on target cells, the missing self-hypothesis. Now it has been 
established that further downstream signalling is required via activating receptors. 
This was proven by showing that monoclonal antibodies to NKp30 and NKp44 were 
capable of blocking NK cell-mediated killing (Pende et al., 1999, Vitale et al., 1998). 
A table of human NK cell activating receptors and their ligands can be found in table 
1.1. 
Receptor Name Specificity 
BY55 (CD160) HLA-C 
CD16 (FcRIIIA) IgG 
CD25 Unknown 
CD44 Hyaluronan 
CD59 CD2 
CD69 Unknown 
CD94/NKG2C (CD159c) HLA-E 
CD94/NKG2E Unknown 
CRACC (CD319) CRACC (CD319) 
DNAM-1 (CD226) PVR (CD155), CD112 
Lag 3 (CD223) HLA class II 
Leu3 (CD7) SECTM1, galectin 
LFA-1 (CD11a) ICAM1-3 
LFA-2 (CD2) LFA-3 (CD58), CD15 
MAC-1 (CD11b) ICAM-1, fibrinogen 
NKG2D (CD314) MICA/B, ULBP-1-4 
NKp80 AICL 
VLA-4 VCAM-1, fibronectin 
VLA-5 Fibronectin 
Table 1.1. Human NK cell activating receptors and ligands 
1.6.2. Natural cytotoxicity receptors  
 
Natural cytotoxicity receptors (NCRs) are NK cell specific and capable of producing 
a cytotoxic effect without prior sensitisation. NCRs are involved in killing of tumour 
cells (Pessino et al., 1998, Pende et al., 1999) and interact with viral proteins (Arnon 
et al., 2005). The NCRs that have currently been identified are NKp30, NKp46 and 
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NKp80 that are expressed on resting and activating NK cells and NKp44 that is only 
expressed on activated cells (Moretta et al., 2000). A table of the known NCRs 
associated ligands can be found below in table 1.2 (Kruse et al., 2014). 
NCR Ligand Signal Reference 
NKp30 HA of the ectromelia and vaccinia virus Inhibition (Jarahian et al., 2011) 
 Released pp65 of the human 
cytomegalovirus 
  
Inhibition 
(Arnon et al., 2005) 
 PfEMP1 of Plasmodium falciparum Activation (Mavoungou et al., 2007) 
 Heparin and heparan sulphates Activation (Hecht et al., 2009, 
Bloushtain et al., 2004) 
 BAT3 on tumour cells, stressed cells and 
DC 
Activation (Pogge von Strandmann et 
al., 2007) 
 B7-H6 on tumour cells Activation (Li et al., 2011, Brandt et 
al., 2009) 
NKp44 HA and HN of the influenza virus, Sendai 
virus and Newcastle disease virus 
Activation (Jarahian et al., 2009, 
Arnon et al., 2001, 
Chisholm and Reyburn, 
2006) 
 Envelope glycoprotein of the Dengue and 
West Nile viruses 
Activation (Hershkovitz et al., 2009) 
 Unknown ligand of Mycobacterium 
tuberculosis, M. bovis, Nocardia farcinica 
and Pseudomonas aeruginosa 
Activation (Esin et al., 2008, Esin et 
al., 2013) 
 Heparin and heparan sulphates Activation (Hecht et al., 2009) 
 PCNA expressed on tumour cells Activation (Rosental et al., 2011, 
Horton et al., 2013) 
 NKp44L expressed on tumour cells and 
bystander CD4+ cell during HIV infection 
Activation (Baychelier et al., 2013, 
Vieillard et al., 2005, 
Vieillard et al., 2008) 
NKp46 HA and HN of the influenza virus, Sendai 
virus, Newcastle disease virus, ectromelia 
virus and vaccine virus 
Activation (Mandelboim et al., 2001, 
Jarahian et al., 2009, 
Jarahian et al., 2011) 
 Vimentin expressed on M. tuberculosis-
infected cells 
Activation (Garg et al., 2006) 
 Unknown ligand of Fusobacterium 
nucleatum 
Activation (Chaushu et al., 2012) 
 PfEMP1 of Plasmodium falciparum Activation (Mavoungou et al., 2007) 
 Heparin and heparan sulphates Activation (Hecht et al., 2009, 
Bloushtain et al., 2004) 
 Unknown ligand on pancreatic  
Langerhans cells 
Activation (Gur et al., 2011, Gur et 
al., 2013) 
BAT3, HLA-B-associated transcript 3; DC, dendritic cell; HA, haemagglutinins; 
HIV, human immunodeficiency virus; HN, haemagglutinin neuraminidases; NCR, 
natural cytotoxicity receptor; PCNA, proliferating cell nuclear antigen; Plasmodium 
falciparum erythrocyte membrane protein-1 (PfEMP1). 
Table 1.2. NCRs and associated ligands. License obtained from Nature 
Publishing Group; 4025231168249. 
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1.6.3. CD94/NKG2C/E 
 
The NK cell group 2 (NKG2) is a family of C-type lectin receptors that comprise of 
NKG2C and NKG2E and are specific for HLA-E. They are expressed as 
heterodimers coupled with the membrane glycoprotein CD94. Both heterodimers 
signal via DAP10 and have been implicated in viral immunity (Braud et al., 1998, 
Fang et al., 2011). The preferential expansion of a CD94/NKG2C NK cell subset has 
been observed after infection with cytomegalovirus (CMV), chronic hepatitis B 
(HBV) and hepatitis C (HCV) (Beziat et al., 2012) and further a high level of highly 
functional CD94/NKG2C+ and CD57+ NK cells have been detected in CMV infected 
individuals (Lopez-Verges et al., 2011). Following HSCT reactivation of CMV has 
shown to promote the expansion of CD94/NKG2C+ NK cell subset that have a 
mature NK cell phenotype, enhanced IFN- production and an extended lifespan. 
Such characteristics suggest a memory-like NK cell phenotype (Foley et al., 2012, 
Min-Oo et al., 2013).  
 
1.6.4. NKG2D 
 
NKG2D belongs to the CD94/NKG2 family of C-type lectin-like receptors and is a 
transmembrane protein that signals via the DAP10 molecule (Wu, 1999). Almost all 
NK cells as well as a subset of CD8 T cells and  T cells express NKG2D and it 
binds to MHC class I related chain A/B (MICA/MICB) molecules and UL-16 
binding proteins (ULBPs) (Bauer et al., 1999, Cosman et al., 2001). NKG2D 
mediated NK cell activation is capable of overriding KIR mediated inhibition as the 
signalling cascade for DAP10 is not affected by SHP, a component of immune 
tyrosine-based inhibitory motifs (ITIM) bearing receptors (Watzl and Long, 2003). 
Many epithelial tumours express ligands for NKG2D (Jinushi et al., 2003) and 
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recognition enhances effector cell function against these cancerous cells (Raulet, 
2003). Soluble ligands for NKG2D have however been detected in leukaemia 
patients that impair NK cell function (Salih et al., 2003). Interestingly soluble 
NKG2D ligands have also been found in umbilical cord blood (CB) plasma 
indicating a possible role in foetal/maternal tolerance (Cox et al., 2015). 
1.6.5. CD16 
 
CD16 (FcRIII) recognises antibody bound on stressed cells via the Fc portion of 
IgG initiating ADCC, a pathway that promotes apoptosis of target cells (Lanier et al., 
1991). NK cell activation via CD16 is extremely potent and is the only receptor 
capable of initiating cytotoxicity without synergy with other receptors (Bryceson et 
al., 2006b).  
 
1.6.6. Killer Ig-like receptors  
 
The KIRs family are polymorphic, versatile and capable of acting as both activating 
and inhibitory receptors (Yawata et al., 2002). Activating KIRs have a short 
cytoplasmic tail without any signalling motif associating with the immunoreceptor 
tyrosine-based activation motif (ITAM) DAP12 (Biassoni et al., 1996).  
 
Inhibitory KIRs contain either two (KIR2D) or three (KIR3D) immunoglobulin (Ig)-
like long extracellular domains (Biassoni et al., 2001). KIR2D bind HLA-C alleles 
whereas KIR3D bind HLA-A or B alleles. Ligation of inhibitory KIRs utilises the 
ITIM pathway that recruits SHP-1 and SHP-2 that are responsible for inhibition of 
numerous NK cell functions (Lanier, 2005). A table of activating and inhibitory 
KIRs and known ligands can be found in Table 1.3. 
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Receptor Name Signal Specificity 
KIR2DS1 Activating Group 2 HLA-CAsn77 Lys80 
KIR2DS2 Activating Group 1 HLA-CSer77 Asn80 
KIR2DS3-6 Activating Unknown 
KIR3DS1 Activating Unknown 
KIR2DL4 (CD158a) Activating/Inhibitory HLA-G (soluble) 
KIR2DL1 Inhibitory HLA-Cw4 
KIR2DL2 Inhibitory HLA-Cw3 
KIR2DL3 Inhibitory HLA-Cw3 
KIR3DL1 Inhibitory HLA-Bw4 
KIR3DL2 Inhibitory HLA-A3 and HLA-A11 
Table 1.3. Human NK cell activating and inhibitory KIRs. 
 
1.6.7. Inhibitory receptors 
 
NK cell activation is further regulated by the expression of inhibitory receptors. As 
mentioned above some of these receptors belong to the KIR family and recognise 
MHC class I. The C type lectin receptors (CD94/NKG2A) bind HLA-E. NK cells 
express a minimum of one inhibitory receptor to avoid killing of healthy self-cells. 
Aside from the inhibitory KIRs other inhibitory receptors and ligands can be found 
in table 1.4. The ligation pathway common to inhibitory receptors is characterised by 
tyrosine phosphorylation of ITIM that recruit Src homology 2 domain-containing 
phosphastases (Lanier, 2005). 
 
1.6.8. CD94/NKG2A 
 
The CD94/NKG2A complex binds the non-classical MHC class I molecule HLA-E. 
HLA-E assembles at the endoplasmic reticulum (ER) via leader peptides from HLA-
A, B and C (Braud et al., 1997). NK cells use the CD94/NKG2A-HLA-E interaction 
as a key mechanism for monitoring MHC class I molecules as if MHC class I 
downregulation occurs, HLA-E expression is also reduced (Kaiser et al., 2005). The 
remaining inhibitory receptors can be seen in table 1.4. 
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Receptor Name Specificity 
CCR6 MIP-3 
CD94/NKG2A HLA-E 
Siglec 7 and 9 Collagen 
Table 1.4. Other human NK cell inhibitory receptors 
 
1.7. Natural killer cell killing mechanisms 
 
NK cells have two distinct effector functions referred to as target cell elimination and 
cytokine secretion (Vivier et al., 2008).  
 
1.7.1. Perforin and granzymes 
 
After target recognition and formation of an immunological synapse NK cells release 
perforin, a membrane disrupting protein and granzymes, a family of serine proteases 
(Smyth et al., 2005). After their release from lysosomes perforin disrupts endosomal 
trafficking by binding to the phospholipid components of the lipid bilayer and 
facilitating entrance of granzymes in the cell, these then induce apoptosis or 
programmed cell death (Lavrik et al., 2005).  
 
1.7.2. Death receptors 
 
NK cells are also capable of eliminating targets via the engagement of cell surface 
death receptors. Members of the tumour necrosis factor (TNF) family Fas ligand 
(FasL) and TNF-related apoptosis-inducing ligand (TRAIL) are able to induce target 
cell apoptosis by engagement of their receptors with target cells (Lavrik et al., 2005). 
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1.7.3. Cytokines 
 
NK cells release a variety of cytokine that assist with target cell elimination and 
provide activation signals for other immune cells. NK cells produce IFN- in 
response to cytokines produced by other immune cells and upon recognition of target 
cells via activating receptors. The secreted IFN- then plays key roles in the 
mediation in anti-tumour and anti-microbial responses. TNF- is released after 
engagement of NKp30 with DCs (Vitale et al., 2005) that then enhances NK cell 
cytotoxicity by upregulating adhesion molecules (Wang et al., 2012). NK cells are 
also capable of producing high levels of GM-CSF that stimulates HSC to produce 
granulocytes to combat infection (Cooper et al., 2001). The secretion of the pro-
inflammatory cytokines IL-2, IL-6, IL-8 and IL-12 enhance the activation and 
proliferation of T cells, macrophages and DCs (Elenkov and Chrousos, 2002). NK 
cells also release chemotatic cytokines (chemokines) that play a role in directing 
immune cells to various target sites. Signalling required for chemokine and cytokine 
production are distinct from those for degranulation, NK cell cytotoxicity (Bryceson 
et al., 2009) and secretion of cytotoxic granules (Reefman et al., 2010), allowing 
each process to occur independently of one another. 
 
1.7.4. Priming 
 
NK cell function has always been believed to be independent of prior stimulation. 
However recent work in mice (Ganal et al., 2012, Lucas et al., 2007) and humans 
(Bryceson et al., 2006a, North et al., 2007, Sabry et al., 2011) has shown that NK cell 
priming is required to produce full NK cell effector functions. NK cells can be 
primed in vivo by DCs that can produce and trans-present IL-15 stimulating resting 
NK cells to produce a cytotoxic effect and release cytokines (Lucas et al., 2007). 
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Mononuclear phagocytes have also shown to prime NK cells during viral infection 
(Ganal et al., 2012). Incubation with IL-2 has been shown to be a requirement to 
observe natural cytotoxicity against target cells expressing a single ligand for NK 
cell activation (Bryceson et al., 2006b). Further studies have shown that pre-
treatment with IL-12 or IL-15 enhances cytotoxicity and cytokine production against 
tumour cells (Hart et al., 2005, Strowig et al., 2010). Additionally it has been shown 
that tumour cells can prime resting NK cells to kill previously resistant targets (North 
et al., 2007). NK cell priming therefore appears to be a highly potent activation 
method for improving NK cell cytotoxic function. 
 
1.8. Specialised NK cells 
 
1.8.1. Innate Lymphoid cells (ILCs) 
ILCs have been demonstrated to play a role in infection control, adaptive immune 
regulation and tissue development and repair (McKenzie et al., 2014, Diefenbach et 
al., 2014). They do not express antigen receptors or undergo clonal selection and 
expansion when stimulated. Alternatively ILCs react readily to signals from infected 
or injured tissues and produce an array of cytokines. Three distinct groups of ILCs 
have been identified based upon their immune response, type 1 are characterised by 
their release of IFN- and NK cells are included within this group. Group 2 cells 
produce IL-15 and IL-13 and group 3 comprise of IL-22 and IL-17 producers. ILC 
development is dependent on the transcription factor ID2 and a full depiction of ILC 
development can be seen in figure 1.8. 
ILC1s are regulated by T-BET and similar to NK cells differentiate without 
recombination and therefore lack antigen receptors encoded by rearranged genes. 
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The high plasticity of ILC1s and modulation of receptors during an immune response 
means it can be extremely difficult to distinguish them from NK cells (Spits et al., 
2016). ILC1s have however been reported in the spleen, liver, intestine, and 
peritoneal cavity of mice and can be discriminated from NK cells by the expression 
of the transcription factors T-BET and EOMES where NK cells are T-BET+EOMES+ 
while ILC1 are T-BET+EOMES− (Daussy et al., 2014). GATA-3 has been shown to 
be critical for ILC1 development (Yagi et al., 2014) yet its relevance in NK cell 
development remains unclear (Samson et al., 2003). Although both subsets produce 
IFN- ILC1s have been reported to predominantly produce TNF- whilst NK cells 
are capable of cytotoxicity via production of perforins and granzymes which so far is 
unconfirmed in ILC1s. It has been hypothesised that ILC1 cells play a role in the 
defense against intracellular bacteria and protozoa (McKenzie et al., 2014). 
ILC2s are the most homogenous of the innate lymphoid cell populations expressing 
IL-7Ra, IL2Ra, Sca-1, KLRG1, and the IL-33 receptor ST2 in all tissues. 
Additionally they are dependent on GATA-3, RORα, TCF-1 and Notch for their 
development (Diefenbach et al., 2014). ILC2s have been implicated in the priming 
and differentiation of the TH2 immune response (Mirchandani et al., 2014). 
Group 3 ILCs are a much more complex cluster and many different subsets have 
been observed in adult mice. They can be grouped together by the expression of 
RORT and production of IL-22 and IL-17 but their expression of other cell surface 
markers and cytokine production profiles vary (Cortez et al., 2015). ILC3s require 
RORT and AHR for development, and can be further characterised by their 
expression of NKp46 and CCR6. A subset of ILC3s previously referred to as NK-22 
cells secrete high levels of IL-22, IL-26 and leukaemia inhibitory factor that is 
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believed to mediate epithelial protection and have an innate anti-inflammatory role 
(Cella et al., 2009). 
 
 
Figure 1.8. ILC development. Schematic of ILC development in the BM and 
periphery. ILCs are divided into group 1, group 2, and group 3 based on common 
receptors and effector cytokine production. 
 
1.8.2. Liver  
 
NK cells comprise around 50 % of total hepatic leukocytes with equal proportions of 
CD56bright and CD56dim NK cells (Norris et al., 1998). Liver NK cells are 
differentiated from NKP that circulate from the BM and possess a distinct phenotype 
(Moroso et al., 2011). CD56bright liver NK cells express significantly higher levels of 
CD69, NKp44 and HLA-DR and less L-selectin than PB CD56bright NK cells. 
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CD56dim liver NK cells express less KIRs and have reduced cytotoxicity in 
comparison to PB CD56dim NK cells (Burt et al., 2009). It has now been well 
established that two populations of liver NK cells are present; liver resident and 
conventional liver NK cells. The solely liver resident NK cell population has been 
shown to be long-lived and EOMEShi (Cuff et al., 2016). Further an expanded 
population of immature CD16- murine NK cells has been identified that may traffic 
from the blood and then differentiate into hepatic-specific CD49a+ and CXCR6+ NK 
cells. Whilst the function of this subset is currently unknown terminally 
differentiated NKG2C+ cells show KIR expansion in the human liver and could 
represent an antigen-experienced population. This could imply that the liver may be 
a site of NK cell memory acquisition (Hydes et al., 2015). 
 
1.8.3. Thymic 
 
Thymic NK cells express high levels of CD56, CD127 and GATA-3. Thymic NK 
cells produce IFN-, TNF-, GM-CSF but have a lower killing capacity that 
correlates with lower expression of granzyme B in comparison to spleen NK cells 
(Vosshenrich et al., 2006). 
 
1.8.4. Uterine 
 
During the first trimester of pregnancy uterine NK (uNK) cells comprise around 70% 
of the mononuclear cells in the womb (Bulmer et al., 1991). uNK cells have a poor 
cytotoxic function instead playing a supportive role in vascular remodelling and 
placental growth (Hanna et al., 2006). A majority of uNK cells are CD56brightCD16− 
and express numerous activating receptors including NKG2D, NKp30, NKp44 and 
NKp46 (Tabiasco et al., 2006, Hanna et al., 2006). As uNK cells interact with 
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trophoblasts it stimulates the production of pro-angiogenic molecules regulating 
trophoblast invasion (Moffett-King, 2002). The interaction of NKp44 and NKp30 
expressed by uNK cells with ligands expressed by stromal decidual cells and 
trophoblasts induces the production of vascular endothelial growth factor (VEGF), 
placenta growth factor (PIGF), angiopoietins and TGF-1 (Vacca et al., 2011, 
Moffett-King, 2002). Trophoblast cells also secret HLA-G as soluble ligands that 
bind KIR2DL4 promoting the induction of pro-angiogeneic cytokines. Further the 
production of IL-8 and CXCL10 promote the migration of extravillous trophoblast 
cells towards the decidual basalis (Hanna et al., 2006). 
 
1.8.5. Salivary gland 
 
So far only found in mice, salivary gland (SG) NK cells do not express CD117 but 
express mature NK cell markers NKp46, TRAIL, CD11b, DX5, Ly49s and CD43. 
They possess a limited capacity to produce IFN-γ and degranulate and are not 
regulated by iNKT or Treg cells, which are mostly absent in the salivary gland 
(Tessmer et al., 2011). Further SGNK cells have been shown to differentiate in a 
nuclear factor, interleukin-3 regulated (NFIL3) independent fashion and in the 
absence of MCMV infection (Cortez et al., 2014). 
 
1.8.6. Memory-like NK cells 
 
Immunological memory is an attribute of the adaptive immune system where B and 
T cells are capable of specific recognition of a particular antigen and a robust and 
rapid response upon re-stimulation. It has been estimated that the half-life of mature 
NK cells is 17 days in steady-state conditions (Jamieson et al., 2004) however some 
mature NK cells can be long-lived and produce a strong recall response upon re-
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stimulation. The first evidence of this was demonstrated in a MCMV model where 
NK cells bearing the MCMV specific receptor Ly49H were able to degranulate and 
produce cytokines following reactivation when transferred into a naïve mouse 
challenged with MCMV (Sun et al., 2009). The ability of NK cells to maintain an 
intrinsic memory was later shown in humans by Cooper and colleagues (Cooper et 
al., 2009b). Further after HSCT, specific expansion of the donors NK cells 
expressing inhibitory receptors for ligands missing in the host has been seen 
(Ruggeri et al., 2002, Ruggeri et al., 1999). Protocols have since been developed to 
take advantage of these properties in the hope of yielding long-lived NK cell 
populations with superior effector function. A short in vitro exposure to a 
combination of IL-12, IL-15 and IL-18 produces memory-like NK cells with an 
inheritable superior function and persistence in vitro and in vivo (Romee et al., 
2012).  
 
1.8.7. Cord blood NK cells 
 
Cord blood NK (CBNK) cells constitute 15 – 30 % of total CB mononuclear cells 
(CBMCs) (Kotylo et al., 1990). CD56dim cells make up 90 % of CBNK cells and 
CD56bright constitute the other 10 % showing equal proportions to peripheral blood 
NK (PBNK) cells (Tanaka et al., 2003, Dalle et al., 2005). Studies on CBNK 
function have shown some inconsistent results. CBNK cells have been shown to be 
less cytotoxic than PBNK cells however they were responsive to IL-2 and IL-12 
(Gaddy et al., 1995). The reduced function of CBNK cells has been attributed to the 
higher expression of NKG2A/CD94 inhibitory receptors and lower expression of 
granzyme B (Wang et al., 2007). Our group has previously carried out an extensive 
comparison of CBNK cells and PBNK cells (Luevano et al., 2012). This showed that 
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the percentage of CD56bright NK cells was higher in CB than PB in contradiction to 
other reports (Tanaka et al., 2003, Dalle et al., 2005). Levels of CD94/NKG2A were 
higher and levels of granzyme B, perforin and Fas-ligand were lower indicating a 
reduced killing capacity. There was no difference in the percentage expression of 
NKG2D but the MFI was lower on CB than on PB. Levels of degranulation were 
comparable with PBNK cells in response to the K562 cells but CBNK cells were not 
able to lyse the K562 cells without prior activation (Luevano et al., 2014, Luevano et 
al., 2012). 
 
1.9. Cancer immunotherapy 
 
Cancer immunotherapy aims to harness a patient’s immune system to target tumour 
cells more efficiently. There are numerous methods of immunotherapy that involve 
the administration of cytokines, antibodies or cells to assist with the eradication of 
malignancies. Cellular immunotherapy involves the administration of autologous or 
allogeneic immune cells that have an anti tumour activity or are involved in its 
stimulation (Armstrong et al., 2001).  
 
1.9.1. Haematopoietic stem cell transplantation 
 
Allogeneic HSCT can be considered a form of immunotherapy as the donor’s 
immune cells are able to target the patient’s malignant cells resulting in a graft versus 
leukaemia effect (GvL), the anti-tumour effect not explained by pre-transplant 
chemotherapy or radiation (Barnes and Loutit, 1957). HSCT involves the 
replacement of a patient haematopoietic system to treat a variety of haematological 
and autoimmune diseases as well as neuroblastoma, ovarian cancer and numerous 
other conditions (Copelan, 2006). 
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1.9.2. Preparative regimens 
 
Chemotherapy and/or radiotherapy are required for the success of HSCT and cancer 
immunotherapy. Such treatments are necessary to reduce tumour burden and 
suppress the immune system of the patient to prevent rejection. Defining the correct 
conditioning regimen is therefore critical. In a transplantation setting common 
regimens are referred to as myeloablative conditioning (MAC) and reduced intensity 
conditioning (RIC). The classification of treatment is often dependent on the drug 
combination and dose of total body irradiation (TBI) used. These can vary 
significantly dependent on the trial. In a recent trial of CBT for adults with AML 
RIC was defined where the TBI dose < 6 Gy in combination with fludarabine or 
busulfan ≤ 8 mg/kg or cyclophosphamide and fludarabine. MAC conditioning 
included a TBI dose ≥ 6 Gy and the association of thiothepa, busulfan and 
fludarabine where the busulfan dose > 8 mg/kg (Baron et al., 2016). Their uses will 
often depend on patient age and disease severity; however any decrease of leukaemia 
recurrence is often at the expense of increased toxicity (Bacigalupo et al., 2009). 
 
The use of new conditioning agents termed “novel agents” have become increasing 
popular in cancer immunotherapy as a result of their immunomodulatory and direct 
tumour targeting mechanisms. In combination with cellular therapy they offer the 
potential for a more personalised and less toxic treatment regimen as these 
specialised drugs have been shown to not only reduce tumour burden but also 
enhance the function of cellular therapies. Although chemotherapy has 
revolutionised the treatment of cancer its side effects include the development of 
refractory disease and in particular severe toxicity. Novel agents provide an 
alternative option of harnessing the immune system to tackle malignancies. 
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Thalidomide was one of the first novel agents to be well studied; it is a synthetic 
glutamic acid derivative that is capable of immunomodulatory, anti-inflammatory 
and anti-angiogenic effects. Although proven successful in targeting multiple 
myeloma the exact mechanism of action of thalidomide is yet to be elucidated 
although anti-inflammatory effects have been attributed to inhibition of TNF- 
production by monocytes and anti-proliferative capabilities to disruption of the BM 
microenvironment preventing multiple myeloma cellular development (Morgan and 
Davies, 2013). Although extended anti-angiogeneic characteristics make a desirable 
option in limiting tumour development its immunomodulatory properties haven’t 
been so well defined. Lenalidomide is an immunomodulatory compound with a dual 
mechanism of action. It is capable of targeting the tumour directly through stromal 
support disruption, induction of tumour suppressor genes and activation of caspases 
(Davies and Baz, 2010). It is also able to stimulate the cytotoxic functions of NK 
cells and T lymphocytes whilst limiting the immunosuppressive impact of regulatory 
T cells (Semeraro et al., 2013). Additionally Bortezomib is a proteasome inhibitor 
proven popular by up regulating expression of TRAIL death receptors and altering 
caspase-8 activity rendering tumours susceptible to NK cell lysis. With T cells using 
a similar death receptor the same outcome is expected, intriguingly these tumours 
acquire resistance to T cell cytotoxicity (Lundqvist et al., 2010). The specific 
mechanisms by which novel agent function offer a promising future for the treatment 
of a variety of malignancies as these agents target not only the tumour themselves 
but also offer potential to enhance the immune system. This provides the possibility 
of coupling cellular therapy with novel agents to provide personalised treatment 
regimens to target an individual’s condition. A summary of novel agents highlighting 
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their impact on NK cells and other immune cells can be found below in table 1.5 
(Krieg et al., 2010). 
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Drug Direct effect on NK cells Indirect effect on NK cells 
Immunomodulatory drugs 
Thalidomide • Increased NK cell numbers after therapy in MM patients 
(Davies et al., 2001) 
• Increased cytotoxicity toward MM tumour cells (Davies et 
al., 2001) 
• T cell stimulation leading to increased ADCC and 
cytotoxicity of NK cells towards K562 and MM tumour 
cells (Hayashi et al., 2005) 
 
Lenalidomide • No effect on proliferation of NK cells in vitro (Dauguet et al., 
2010) 
• Increased NK cell numbers in metastatic MM and other 
advanced cancer patients (Bartlett et al., 2004) 
• Increased numbers of NKp44+ NK cells in MM patients with 
relapse (Lioznov et al., 2010) 
• Upregulation of CD56, CD16, CD40L, and LFA1 (Tai et al., 
2005, Dauguet et al., 2010) 
• Downregulation of SOCS1, NKAT2, NKB1, CD158a, and 
NKp46 (Dauguet et al., 2010, Gorgun et al., 2010) 
• Increased cytotoxicity toward MM tumour cells (Davies et 
al., 2001) 
• Inhibition of IFN-γ production by activated NK cells 
(Dauguet et al., 2010) 
• Increased NK cell numbers and activation in RAJI-bearing 
SCID mice via stimulation of DCs and their cytokines 
(Reddy et al., 2008) 
• T cell stimulation leading to increased ADCC and 
cytotoxicity of NK cells toward K562 and MM tumour cells 
(Hayashi et al., 2005) 
Ponalidomide • Downregulation of SOCS1 (Gorgun et al., 2010) 
• Increased cytotoxicity toward MM and K562 tumour cells 
(Davies et al., 2001, Payvandi et al., 2005) 
• Increased NK cell numbers and activation in RAJI-bearing 
SCID mice via stimulation by DCs and their cytokines 
(Reddy et al., 2008) 
• T cell stimulation leading to increased ADCC and 
cytotoxicity of NK cells toward K562 and MM tumour cells 
(Hayashi et al., 2005) 
• Upregulation of CD69 (Payvandi et al., 2005) 
• Increased IFN-γ production (Payvandi et al., 2005) 
Tyrosine Kinase Inhibitors 
Imatinib • Increased NK cell numbers post therapy (Ohyashiki et al., 
2012) 
• Downregulation of NKG2DL on K562 and CML tumour 
cells leading to reduced cytotoxicity and IFN-γ production 
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• No impact on cytotoxicity and cytokine production in vitro 
(Salih et al., 2010) 
• Increased NKp30- and NKG2D-dependent lysis and IFN- 
γ production in gastrointestinal stromal tumour patients 
(Menard et al., 2009) 
• Increased IFN-γ production in gastrointestinal stromal 
tumour patients correlated with clinical outcome (Borg et al., 
2004) 
(Salih et al., 2010) 
• Downregulation of ICAM-1 on BCR/ABL-transfected 
leukaemic tumour cells accompanied by decreased 
cytotoxicity (Baron et al., 2002) 
• DC stimulation leading to increased NK cell activity in 
human and mice (Borg et al., 2004) 
Nilotinib • Inhibition of cytokine production but no effect on 
cytotoxicity (Salih et al., 2010) 
• Downregulation of NKG2DL on K562 and CML tumour 
cells leading to reduced cytotoxicity and IFN-γ production 
(Salih et al., 2010) 
Dasatinib • Inhibition of cytotoxicity in mice (Fraser et al., 2009) 
• Inhibition of cytotoxicity toward K562 and cytokine 
production (Salih et al., 2010) 
• Downregulation of NKG2DL on K562 and CML tumour 
cells leading to reduced cytotoxicity and IFN-γ production 
(Salih et al., 2010) 
Sorafenib • Inhibition of cytotoxicity and cytokine production (Krusch et 
al., 2009) 
• Increase of MICA on HCC tumour cells and decrease of 
soluble MICA leading to enhanced cytotoxicity (Kohga et 
al., 2010) 
• Increased expression of NKG2DL on nasopharyngeal 
carcinoma cells leading to enhanced cytotoxicity (Huang et 
al., 2011) 
Sunitinib • Inhibition of cytotoxicity and cytokine production only in 
unphysical high doses (Krusch et al., 2009) 
• Increased expression of NKG2DL leading to enhanced 
cytotoxicity (Huang et al., 2011) 
Proteasome Inhibitors 
Bortezomib • Pro-apoptotic effect on resting NK cells (Wang et al., 2009) 
• Downregulation of NKp46 resulting in diminished activity 
(Wang et al., 2009) 
• Inhibition of cytotoxicity of activated NK cells toward MM 
tumour cells (Feng et al., 2010) 
• Induction of DR5 on renal cell carcinoma leading to 
enhanced susceptibility (Lundqvist et al., 2006) 
• Upregulation of NKG2DL on diverse cell lines and head 
and neck squamous cell carcinoma cells leading to enhanced 
susceptibility (Vales-Gomez et al., 2008, Butler et al., 2009) 
• Increased caspase 8 activity leading to enhanced 
susceptibility toward murine and human tumours (Lundqvist 
et al., 2009) 
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• Downregulation of HLA class 1 on human MM and MHC 
class I on murine leukaemic tumour cells (Hallett et al., 
2008, Shi et al., 2008b)(Hallett 2008, Shi 2008) 
• Upregulation of DNAM-1 and NKG2DL in primary 
plasma cells and NKG2DL on B-ALL tumour cells leading 
to increased degranulation of NK cells (Soriani et al., 2009, 
Jardine et al., 2013) 
Table 1.5. The effect of novel agents on NK cells. Modified from Krieg and Ullrich 2012. 
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1.9.3. HSC sources 
 
Until recently BM was on the only source of HSCs and it is collected by aspiration 
from iliac crests of donors under anaesthesia. A major complication of bone marrow 
transplantation (BMT) is graft versus host disease (GvHD). T cell depletion of the 
graft is therefore often performed to avoid GvHD that in turn runs the risk of relapse 
(Lan et al., 2003). 
 
GvHD presents itself in two forms; acute and chronic. The incidence of acute GvHD 
can be related to the degree of mismatch between HLA proteins and ranges from 35-
45% in recipients of full matched sibling donor grafts (Loiseau et al., 2007, 
Ratanatharathorn et al., 1998) to 60-80% in recipients of one-antigen HLA 
mismatched unrelated donor grafts (Flomenberg et al., 2004). The severity of acute 
GvHD is determined by the extent of involvement of the skin, gastrointestinal tract 
and liver and can be classified in 6 stages from mild to severe (Vogelsang et al., 
2003). The development of acute GvHD can be hypothesised into three sequential 
phases: (1) activation of the APCs; (2) donor T cell activation, proliferation, 
differentiation and migration; and (3) target tissue destruction (Ferrara et al., 2009). 
Acute GvHD develops within 100 days of transplantation (Jagasia et al., 2015) and 
steroids are the current gold standard of treatment with their potent anti-lymphocyte 
and anti-inflammatory effects (Ferrara et al., 2009). Chronic GvHD occurs beyond 
100 days of transplantation (Jagasia et al., 2015) and is the major cause of late non-
relapse death following HSCT (Lee et al., 2002). In comparison to acute GvHD the 
pathophysiology of chronic GvHD remains poorly understood, it is treated with a 
variety of immunosuppressive agents where responses are often unpredictable 
(Ferrara et al., 2009). 
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PB contains low numbers of HSCs however following administration of mobilising 
agents such as granulocyte-colony stimulating factor (G-CSF) HSCs can be collected 
in large quantities via aphaeresis (Bensinger and Storb, 2001). Due to the large 
numbers of cells obtained, mobilised PB aphaeresis aids faster engraftment of 
neutrophils and earlier lymphocyte reconstitution. The incidence of chronic GvHD 
can sometimes be higher in comparison to BMT (Schmitz et al., 2005). 
 
CB is increasingly becoming an alternative source of HSC following the first 
successful cord blood transplantation (CBT) in a patient with Fanconi anaemia in 
1988 (Gluckman et al., 1989). There are over 600,000 CB units available worldwide 
and its off-the-shelf availability and less stringent HLA-matching (Wagner et al., 
1996) have clinical advantages over other HSC sources. Further CBT presents lower 
incidence and severity of GvHD whilst preserving GvL however immune 
reconstitution is slow rendering recipients highly susceptible to infection (Rocha et 
al., 2001). Due to low HSC numbers present in CB units a majority of CBT 
procedures have initially been performed in children. However many strategies have 
recently been developed to overcome this such as double cord infusion (Barker et al., 
2005), intra bone injection (Frassoni et al., 2010), ex-vivo expansion of CB HSC (de 
Lima et al., 2012), the use of prostaglandin derivatives to improve homing and 
induce haematopoietic progenitor proliferation (Cutler et al., 2013), ex-vivo 
fucosylation to accelerate neutrophil and platelet engraftment (Popat et al., 2015) and 
co-administration of CB derived accessory cells such as NK cells (Danby and Rocha, 
2014, Escobedo-Cousin et al., 2015).  
 
54 
 
Immune reconstitution can be defined as the recovery of a fully functional immune 
system post HSCT. Generally speaking NK cells are the first immune cells to 
reconstitute implying they play a key role in mediating GvL. CD8+ T cell 
reconstitution begins 4 months post transplant and CD4+ T cells reach normal levels 
within 9 to 12 months. B cells can take up to 12 months to recover (Petersen et al., 
2003).  
 
1.9.4. HSCT complications 
 
As a result of immunosuppressive drugs and delayed immune reconstitution patients 
are often susceptible to many complications. Early difficulties include viral 
infections such as CMV and EBV reactivation (Boeckh et al., 2003, Brunstein et al., 
2006) and graft failure. Graft failure corresponds with lack of engraftment of donor 
cells or graft rejection by host’s immune cells, incidence increases in a HLA-
mismatched transplantation, unrelated transplantation and patients treated with 
reduced intensity regimens (Mattsson et al., 2008). Donor cells are also capable of 
attacking the host’s healthy cells in a condition known as GvHD (Przepiorka et al., 
1999). This condition often occurs as a result of HLA-mismatch however HLA 
matched recipients may still be at risk as a result of minor histocompatibility antigen 
mismatch (Warren et al., 2012).  
 
1.9.5. Role of NK cells in HSC transplantation 
 
NK cells are the first population to reconstitute post HSCT and an important role in 
mediating immunity against tumour cells and infection. NK cells are also capable of 
providing a supportive effect during HSCT as donor NK cells have the potential to 
provide an allo-reactive effect and kill leukaemia cells without initiating GvHD. The 
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direct involvement of allogeneic NK cells in inducing anti-tumour effect in HSCT 
was first demonstrated in 2002 (Ruggeri et al., 2002). Allo-reactive NK cells were 
shown to enhance engraftment; providing GvL effect whilst suppressing GvHD 
particularly when a KIR ligand mismatch in the donor to host direction was observed 
(Ruggeri et al., 2006). Donor KIR genotype has the potential to influence outcomes 
of unrelated HSCT for haematological malignancies and the KIR group B genotype 
implies a significant survival benefit to patients (Impola et al., 2014, Cooley et al., 
2009). To utilise the allo-reactive impact of KIR-ligand mismatch in a 
transplantation setting algorithms have been developed to ensure the selection of the 
best possible donor for HSCT (Miller et al., 2005). High donor KIR group B has 
been associated with significantly reduced relapse in children after haploidentical 
HSCT for acute lymphocytic leukaemia (ALL) (Oevermann et al., 2014) and showed 
superior survival after unrelated HSCT for acute myeloid leukaemia (AML) (Miller 
et al., 2005). Although this data is encouraging there have been many other studies 
that have not been able to reproduce the beneficial effects of KIR mismatch (Huang 
et al., 2007, Vago et al., 2008, Brunstein et al., 2009, Leung et al., 2005, Beelen et 
al., 2005). In stark contrast, a majority of investigators actually found overall 
survival to be worst which could be a result of a combination of T cell alloreactivity, 
KIR mismatch definition and misclassifications (Leung, 2011). Research has shown 
that the adoptive transfer of allogeneic NK cells is safe and feasible but further work 
is needed to determine the optimal dose and timing of NK cell therapy. Further it 
should be considered if NK cell activation or expansion is required to achieve 
clinical benefit as well as the involvement of KIR ligand mismatch whilst careful 
consideration must be given to the number of T cells infused as well as the 
supportive drug regimen. 
56 
 
1.10. NK cell immunotherapy 
 
NK cells were initially implicated as playing a role in cancer immunosurveillance 
when one large epidemiologic study found that low NK cell cytotoxicity forecasted 
an increased risk in developing cancer (Imai et al., 2000). Since there have been 
numerous studies demonstrating that NK cells can target human tumours in vivo 
making them a desirable candidate for therapeutic use (Ljunggren and Malmberg, 
2007). An overview of the current results from clinical trials using NK cell 
immunotherapy can be found in table 1.6. 
 
1.10.1. Autologous 
 
Initial studies on the adoptive transfer of NK cells for immunotherapy focused on the 
use of the patient’s own cells. Numerous methodologies have been studied including 
re-infusion of the leukapheresis product with IL-2 (Krause et al., 2004), expansion of 
PBMCs over a tumour cell line (Ishikawa et al., 2004), CD3 depletion and expansion 
over feeder cells (Escudier et al., 1994, Parkhurst et al., 2011) or CD56 selection 
followed by expansion (Lundqvist et al., 2011). All clinical trials were shown to be 
non-toxic however only limited in vivo anti-tumour toxicity was observed (Burns et 
al., 2003), this could be the result of inhibition by self MHC-I as well as detrimental 
side effects associated with the systemic infusion of IL-2 (Baluna and Vitetta, 1997).  
 
1.10.2. Allogeneic 
 
Allogeneic treatment has the potential to offer an alternative therapy with enhanced 
anti-tumour effect. Miller and colleagues were one of the first groups able to 
translate NK cell therapy alone into the clinic. Allo-reactive NK cells were infused 
into patients with advanced cancer alongside IL-2 administration. This demonstrated 
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that NK cell infusions were feasible and safe and led to complete remission in 5/19 
patients with poor prognosis AML (Miller et al., 2005). In the same year two other 
allogeneic NK cell products were shown to be well tolerated with no toxicity 
(Passweg et al., 2004, Koehl et al., 2004). The first trial against myeloma showed an 
impressive 50% complete remission (Shi et al., 2008a). Further it was reported that 
KIR-ligand mismatched donor NK cells could reduce relapse in childhood AML 
(Rubnitz et al., 2010) and were safe for elderly patients with acute AML (Curti et al., 
2011). In addition to IL-2, IL-15 expanded NK cells were shown to be safe and 
potentially clinically effective (Iliopoulou et al., 2010). The efficacy of haplo-
identical NK cell therapy in the refractory disease was further improved by depleting 
host regulatory T cells with IL-2 diphtheria toxin preventing their 
immunosuppressive effect (Bachanova et al., 2014). Expanding NK cells over the 
K562 cells engineered to express membrane bound IL-15 and the co-stimulatory 
molecule 4-1BBL (K562-mb15-41BBL cells) have been shown to rapidly expand an 
NK cell product with an up regulation of activating receptors and improved killing 
capacity (Fujisaki et al., 2009b). However a first-in-human trial performing the 
infusion of donor derived IL-15/4-1BBL activated NK cells showed that 5/9 patients 
experienced acute GvHD (Shah et al., 2014). The T cell content of the infusion was 
well below the specified threshold for GvHD development therefore the group 
concluded that the activated NK donor lymphocyte infusion (DLI) contributed to the 
effect by stimulating underlying T cell allo-reactivity (Shah et al., 2014). This is the 
first time in a clinical setting NK cells have been implicated in the role of induction 
or exacerbation of GvHD. This could be a result of lack of immunosuppressive drugs 
post transplant and infusion of IL-2 that expands immunoregulatory populations 
coupled with the infusion of an expanded NK cell population with such a high up 
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regulation of activating receptors. Current on-going clinical trials include infusing 
NK cells with KIR-ligand mismatch as pre-HSCT conditioning (NCT004024458) 
and NK cell infusions to prevent relapse or treat MRD post HSCT (NCT01386619).  
 
1.10.3. Solid tumours 
 
NK cell immunotherapy could also be used to target solid tumours as the presence of 
NK cells in a tumour mass has been correlated with delayed tumour progression and 
improved outcomes (Gras Navarro et al., 2015) and studies in neuroblastoma, breast 
and ovarian patients have demonstrated that NK cell infusions are safe and partially 
effective (Brehm et al., 2011, Geller et al., 2011). However in addition to tumour 
escape mechanisms trafficking, penetration of cells to the tumour mass and 
resistance to NK cell cytotoxicity maintain to be the biggest hurdles for a successful 
therapy (Murray and Lundqvist, 2016). There is currently limited data on the efficacy 
of NK cells targeting solid tumours but there are currently numerous on-going 
clinical trials against high-risk tumours such as neuroblastoma, ewing sarcoma, 
osteocarcinoma and soft tissue carcinoma (NCT02130869, NCT01807468). 
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Initial 
population 
Feeder cells Fold expansion in 
vitro (purity) 
In vitro 
cytokine admin 
Condition Treatment and in vivo 
cytokine admin 
Dose In vivo expansion Clinical outcome Reference 
Autologous          
CD3 
depleted 
PBMCs 
LCL cell line 
(LAZ388) 
43±26 in 13-21 d 
(90%) 
IL-2 MRC High dose IL-2 + LANAK 
following initial PR to IL-2 
alone 
N/A N/D Induced clinical 
response 15-30% 
patients 
(Escudier et al., 
1994) 
PBMCs None No expansion IL-2 Advanced CRC 
& NSCLC 
Multiple infusions of NK 
cells + IL-2 + Hsp70 
peptide TKD 
1-7.5 x 106/kg Multi-infusion 
trial 
Well tolerated and safe, 
no significant tumour 
response 
(Krause et al., 
2004) 
PBMCs Wilms tumour cell 
line (HFWT) 
113 in 14 d (96%) IL-2 Malignant 
glioma 
Multiple infusions + IFN- N/A Multi-infusion 
trial 
Well tolerated no 
toxicity, 3 PR, 2 MR, 4 
NC and 7 PD 
(Ishikawa et al., 
2004) 
CD3-/CD56+ 
PBMCs 
EBV-LCL (TM-
LCL) 
53-683 in 14 d 
(99.7%) 
IL-2 CLL & 
metastatic 
tumours 
Infusion of NKs + IL-2 
after PEN/BOR 
1 x 108/kg Multi-infusion 
trial 
Well tolerated & some 
pre-clinical evidence of 
anti-tumour response 
(Lundqvist et 
al., 2011) 
CD3- 
PBMCs 
Auto PBMCs 278-1097 in 21-26 d 
(91-97%) 
IL-2 Metastatic 
melanoma & 
RCC 
Infusion of activated NKs + 
IL-2 after CY/FLU regimen 
1.88-7.6 x 
1010/kg 
NK persistence 7 
days post 
infusion 
No toxicity or clinical 
response 
(Parkhurst et al., 
2011) 
Allogeneic          
CD3-/CD56+ 
PBMCs 
N/A No expansion None High risk 
myeloid 
malignancies 
Infusion of NKs post haplo-
HSCT 
0.21-1.41 x 
107/kg 
N/D Well tolerated, 
increased donor 
chimerism in 2/5 
patients 
(Passweg et al., 
2004) 
CD3-/CD56+ 
PBMCs 
None 5 in 12 d (95%) IL-2 Multiple relapse 
ALL & AML 
Repeat infusions of 
activated NKs post-HSCT 
8.9-29.5 x 
106/kg 
N/D Well tolerated, no 
toxicity 
(Koehl et al., 
2004) 
CD3- 
PBMCs 
None No expansion None Metastatic 
melanoma, 
RCC, refractory 
hodgkin’s & 
AML 
Infusion of NKs + IL-2 
after Lo-CY/mPred, FLU or 
Hi-CY/FLU 
1 x 105-2 x 
107/kg 
In vivo NK 
expansion in Hi-
Cy/Flu patients 
CR in 5/19 poor 
prognosis patients 
(Miller et al., 
2005) 
CD3-PBMCs None No expansion IL-2 Myeloma Infusion of activated NKs + 
IL-2 after FLU/MEL 
regimen & auto-PBSCT 
1.7 x 106/kg Donor cells 
persisted and lost 
by day 9-14 
CR in 50% patients (Shi et al., 
2008a) 
PBMCs None 1036 in 19d (88% 
viability) 
OKT3 and IL-2 CRC, carcinoma 
& B-CLL 
Infusion of activated NKs + 
IL-2 after haplo-HSCT 
8.1-40.3 x 
106/kg 
Multi-infusion 
trial 
Minor response in 2 
patients 
(Barkholt et al., 
2009) 
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CD3-/CD56+ 
PBMCs 
None No expansion None AML Infusion of NKs + IL-2 
after CY/FLU regimen 
0.5-8.1 x 
107/kg 
Significant in 
vivo expansion 
observed at day 
14 (5,800/mL) 
100% EFS at 2 years (Rubnitz et al., 
2010) 
CD3- 
PBMCs 
None No expansion 
(43±11%) 
None Lymphoma Infusion of NKs + IL-2 
after RTX/CY/FLU 
0.2-40 x 
107/kg 
NK cells not 
detected 7 days 
post infusion  
2 CR/2PR (Bachanova et 
al., 2010) 
CD3-/CD56+ 
PBMCs 
None 32-131.3 in 20-23 d 
(82.7-99.6%) 
HC and IL-15 Advanced 
NSCLC 
Infusion of pre-activated 
NKs 
0.2-29 x 
106/kg 
Multi-infusion 
trial 
PR in 2 patients best 
response with most 
infusions 
(Iliopoulou et 
al., 2010) 
CD56+ 
selected 
PBMCs 
None No expansion None AML Infusion of NKs + IL-2 
after CY/FLU regimen 
1.11-5.0 x 
106/kg 
Donor NKs 
detected up to 17 
days post first 
infusion 
CR 6/13 patient (Curti et al., 
2011) 
CD3-/CD56+ 
PBMCs 
None No expansion IL-2 for half of 
patients 
AML, ALL, 
neuroblastoma 
& RMS 
Multiple infusions of pre-
activated & resting NKs 
after haplo-HSCT 
6-45.1 x 
106/kg 
NK cells detected 
at 24 hours  
Two patients with 
neuroblastoma alive at 2 
years 
(Brehm et al., 
2011) 
CD3- 
PBMCs 
None No expansion (70% 
viability) 
IL-2 Breast & ovarian 
carcinoma 
Infusion of pre-activated 
NKs + IL-2 after CY/FLU 
wih/without TBI 
8.33 x 106-
3.94 x 107/kg 
No eligible 
patients met pre-
defined criterion 
for successful in 
vivo expansion 
TBI improved longevity 
of NK engraftment 
(Geller et al., 
2011) 
CD56+/CD3- 
PBMCs 
None No expansion None Leukaemia & 
malignant solid 
tumours 
Multiple NK infusions after 
ATG/OKT3 & hapol-HSCT 
0.3-3.8 x 
107/kg 
N/D No Significant clinical 
response 
(Stern et al., 
2013) 
CD56+/CD3/
CD19- 
PBMCs 
None No expansion (53%) IL-2 Relapsed/primar
y AML 
Infusion pre-activated NKs 
after IL-2DT 
2.6±1.5 x 
107/kg 
In vivo expansion 
enhanced with T-
REG depletion 
Well tolerated, no 
toxicity 
(Bachanova et 
al., 2014) 
CD56+CD3- 
PBMCs 
4-1BBL+IL-15R+ 
aAPCs 
9-11 d (>90%) IL-15 EWS, DSRCT 
& RMS 
CY/FLU/MEL/G-CSF 1 x 105/kg Multi-infusion 
trial 
5/9 patients experienced 
acute GVHD 
(Shah et al., 
2014) 
ALL (acute lymphoblastic lymphoma) AML (acute myeloid leukemia) ARCC ATG (anti-thymocyte globulin) B-CLL (B cell chronic lymphocyte leukemia) BOR (bortezomib) CLL (chronic 
lymphocyte leukemia) CR (complete response) CRC (colorectal carcinoma) CY (cyclophosphamide) DSRCT (desmoplastic small round cell tumour) EWS (ewing sarcoma) FLU (fludarabine) 
G- CSF (granulocyte colony stimulating factor) HC (hydrocortisone) MEL (melphalan) MM (multiple myeloma) mPred (methylprednisolone) MRC (metastatic renal carcinoma) N/D (not 
determined) NSCLC (non-small cell lung carcinoma) PEN (pentostatin) PR (partial response) RCC (renal cell carcinoma) RMS (rhabdomyosarcoma) RTX (rituximab) TBI (total body 
irradiation). 
Table 1.6. Summary of current NK cell immunotherapy clinical trials. 
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1.10.4. Tumour escape mechanisms 
 
Tumour cells have evolved the ability to evade the effector functions of the immune 
system. Mechanisms which regulate the evasion of tumour cells by immune cells 
extends to the loss of antigenicity and MHC (Schreiber et al., 2011), reduced NCR 
expression (Costello et al., 2002), down regulation of activating receptor ligands 
(Raffaghello et al., 2004), the production of soluble stress induced ligands that 
degrade NKG2D leading to NK cell inhibition (Groh et al., 2002) and the release of 
suppressive cytokines such as IL-10 and TGF- (Beissert et al., 2006). Furthermore, 
tumour cells are capable of skewing the adaptive response to TH2 immunity that is 
less effective at targeting malignancies (Aruga et al., 1997) and suppress DC 
function by changing the express of IL-6, IL-10 and GM-CSF (Morse et al., 2002).  
 
1.10.5. Antibody based NK cell therapy 
 
To mimic missing self-recognition a monoclonal antibody known as IPH2101 has 
been developed that blocks KIR2DL1, KIR2DL2 and KIR2DL3 receptors on NK 
cells. This has been shown to enhance the lysis of multiple myeloma (Benson et al., 
2011) as well as AML blasts expressing HLA-C in vitro and in vivo (Romagne et al., 
2009). This progressed to a clinical trial against multiple myeloma cells that showed 
the treatment to be well tolerated however no clinical response to the single agent 
was observed (Korde et al., 2014). A further trial in combination with lenalidomide 
was shown to be safe and tolerable with preliminary evidence of efficacy (Benson et 
al., 2015). Additionally there is the possible use of antibodies against tumour 
antigens such CD20 and CS1 to induce ADCC (Moreau, 2012, Benson et al., 2012), 
as well as the use of bi and tri-specific cell engagers to directly activate NK cells 
through CD16 (Gleason et al., 2014).  
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1.10.6. NK cell lines 
 
The use of NK cell lines have been seen as an attractive option due to the availability 
of a clinical grade frozen stock and their homologous nature. The most prominent 
NK cell line currently in focus is the IL-2 dependent NK-92, which was established 
from a patient with non-Hodgkin’s lymphoma. NK-92 has demonstrated its high 
cytotoxicity against a range of malignancies (Klingemann, 2015, Tam et al., 1999) 
and clinical trials have proven non-toxic however they have shown limited success in 
demonstrating efficacy (Arai et al., 2008, Tonn et al., 2013). This could be a result of 
the necessity to irradiate the cell line prior to infusion for safety requirements; the 
cells would therefore be incapable of proliferation in vivo severely limiting their 
persistence and potential to target the tumour. There are currently two further on -
going stage I clinical trials for haematological malignancies (NCT00900809, 
NCT00990717) and a phase II trial using activated NK-92 cells (NCT02465957). 
 
1.10.7. Genetic engineering of NK cells 
 
The use of chimeric antigen receptor (CAR)-expressing NK cells has the potential to 
offer enhanced effector cell function with increased specificity. The NK cells are 
engineered to express antigen receptors against tumour-associated antigens and thus 
redirecting the effector cells and enhancing tumour-specific immunosurveillance. 
Anti-CD19 CAR T cells have effectively demonstrated their ability to induce long-
term remission in patients with B cell malignancies (Grupp et al., 2013). However 
concerns associated with CAR T cell therapy extends to GvHD, on target/off tumour 
effects and tumour lysis syndrome. In contrast allogeneic CAR-engineered NK cells 
are expected to induce anti-tumour effects and dissipate after a few days 
(Klingemann, 2015). Pre-clinical work in the field has been promising and efficacy 
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has been shown against CD19 (Imai et al., 2005, Li et al., 2010, Shimasaki et al., 
2012), CD20 (Chu et al., 2014), CD244 (Altvater et al., 2009) and HER-2 
(Kruschinski et al., 2008). Currently there are two on-going phase I, one using 
donor-derived NK cells that are expanded using the irradiated K562 cell line 
expressing membrane bound IL-15 and 41BB ligand (K562-mb15-41BBL) to target 
B-lineage acute lymphoblastic leukaemia. (NCT00995137) and the other against 
refractory ALL using haploidentical NK cells activated with IL-2 (NCT01974479). 
 
1.10.8. NK cell differentiation from HSC 
 
It is possible to generate high numbers of functional NK cells by differentiation in 
vitro from HSCs or induced pluripotent cells (iPSC). Numerous sources of HSCs 
have previously been used to generate NK cells in vitro. This extends to embryonic 
stem cells (hESC), bone marrow (BM), mobilised peripheral blood stem cells 
(mPBSC) and cord blood stem cells (CBSC). Due to the ethical dilemma posed by 
obtaining HSC from 5-7 day old embryos, hESC are considered a controversial 
source. However the establishment of cell lines have been able to offer different 
perspectives. Previous work using H9 hESC cell line has shown the differentiation of 
NK cells in vitro that express activating and inhibitory receptors, including KIRs, 
and are able to produce cytokines and mediate cytotoxicity in vitro and in vivo (Woll 
et al., 2009, Woll et al., 2005). The use of BM is limited by its invasive collection 
procedure and has therefore been used mainly to study NK cell development (Miller 
et al., 1994, Shibuya et al., 1995). iPSCs offer a desirable source of HSC due to the 
ready availability of a donor and ease of procurement. Recently a method of 
differentiating mature and functional NK cells in vitro using a combination of 
embryoid body formation and membrane-bound IL-21-expressing APCs has been 
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developed (Knorr et al., 2013). The possibility of reprogramming cells is an exciting 
prospect however limitations such as suppression by self-MHC and the risk of 
teratoma development have to be considered.  
 
CB offers an attractive source of CD34+ HSCs due to their off-the-shelf availability 
and non-invasive collection procedure. It has been shown that in the right 
microenvironment it is possible to differentiate mature and functional NK cells from 
CB (Grzywacz et al., 2006). Later a clinical grade differentiation model of NK cells 
from CBCD34+ cells was established that differentiated NK cells that expressed 
NCRs and NKG2A and had a low expression of KIRs and CD16 (Spanholtz et al., 
2010, Spanholtz et al., 2011). These NK cells were used in a phase I dose escalation 
study against poor prognosis AML. Results demonstrated that 30x106 NK cells/kg 
could be safely infused into non-transplant eligible AML patients after 
immunosuppressive chemotherapy and a reduction in minimum residual disease was 
observed in patients receiving hypomethylating agents (Dolstra et al., 2015). 
 
Additionally our group has previously modified an alternative published protocol 
(Grzywacz et al., 2006) and compared the use of mPBSC, fresh CBSC and frozen 
CBSC (Luevano et al., 2014). This work identified frozen CBCD34+ cells to be the 
best source of NK cells over fresh CBCD34+ and frozen PBSCs. This was due to 
higher fold expansion and therefore higher NK cell numbers generated without 
compromising on phenotype, cytokine production or cytotoxicity. Further the cells 
could persist for longer and in higher numbers in vivo. Considering that persistence 
of NK cells in vivo is fundamental for the development of a clinically relevant 
cellular product this makes the differentiation of NK cells from CB HSCs in vitro an 
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attractive candidate for NK cell immunotherapy.  
1.11. Aims of the study 
 
NK cells are capable of mediating a potent anti-tumour response implying an 
immunotherapeutic option to treat cancer. Previously our group has shown that 
frozen CBCD34+ cells generated higher NK cell numbers without loss of function in 
comparison to fresh CBCD34+ cells and mPBCD34+ cells. CBCD34+-NK cells 
expressed low levels of KIR receptors but high levels of activating receptor. 
CBCD34+-NK cells exhibited increased capacity to secrete IFN-γ compared to 
PBCD34+-NK cells and could kill K562 cells in vitro (Luevano et al., 2014). This 
data indicates that the use of frozen CBCD34+ for the production of NK cells in vitro 
results in higher cell numbers than PBCD34+ cells, without losing their function, 
therefore rendering them a suitable source of cells for NK cell immunotherapy. This 
project aims to further characterise NK cells differentiated in vitro from CBCD34+ 
cells with the aim to transplant the therapy to the clinic in the future. We hypothesise 
that CBCD34+-NK cells exhibit a unique phenotype that could translate into a better 
killing of tumour cells over other NK cell sources. For clinical translation of the NK 
cell therapy it is important to assess if CBCD34+-NK cells are capable of killing in 
vivo, if they are able to further proliferate following additional cytokine stimulation, 
if CBCD34+-NK cells can be cryopreserved and still maintain function and how does 
the function of CBCD34+-NK cells compare to NK cells from other sources. The 
experimental aims of this thesis were as follows: 
 
1. Compare the function and phenotype of CBCD34+-NK cells to that of freshly 
isolated PBNK cells and CBNK cells (chapter 3). 
2.  Classify the best form of activation of CBCD34+-NK cells (chapter 4). 
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3. Identify if CBCD34+-NK cells can be cryopreserved and still maintain 
function (chapter 5). 
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Chapter 2 
  
Chapter 2 
 
Materials and Methods 
Chapter 2 Materials and Methods 
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2.1. Materials 
 
The media used in cell culture is listed in table 2.1. 
 
Culture Media Provider Location 
Alpha MEM without L-glutamine Lonza Verviers, Belgium 
Dulbecco’s Modified Eagle Medium 
(DMEM) high glucose with L-glutamine 
Lonza Verviers, Belgium 
HAM’S F12 Lonza Verviers, Belgium 
Myelocult Stem Cell Tech Grenoble, France 
RPMI 1640 Lonza Verviers, Belgium 
Table 2.1. Cell culture reagents. 
 
The serum used in cell culture is listed in table 2.2. 
 
Serum Provider Location 
Bovine serum albumin (BSA) Sigma Poole, UK 
Foetal bovine serum (FBS) Lonza Verviers, Belgium 
Human serum type AB (AB serum) Lonza Verviers, Belgium 
Mouse serum Sigma Poole, UK 
Table 2.2. Serums. 
 
The kits used for cell processing are present in table 2.3. 
 
Table 2.3. Cell isolation and labelling kits. 
 
Additional solutions and reagents used for experiments can be found in table 2.4. 
 
Kit Provider Location 
Carboxyflourescein succinimidyl 
ester (CFSE) 
Life Technologies UK 
CD34 Microbead kit Miltenyi Biotec Bergisch Gladbach, Germany 
Cytofix/CytopermTM plus BD Biosciences USA 
Human granulocyte depletion kit Stem Cell Technologies Grenoble, France 
NK cell isolation kit Miltenyi Biotec Bergisch Gladbach, Germany 
PKH26 fluorescent cell linker kit Sigma Poole, UK 
Telomere PNA Kit/FITC Dako Denmark 
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Table 2.4. Solutions and reagents. 
 
Further buffers used in experimentation can be seen in table 2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
Solution/Reagent Provider Location 
1450 microbeta plus liquid scintillation 
counter 
Perkin Elmer Cambridgeshire, UK 
Ascorbic acid Sigma Cambridgeshire, UK 
BD Pharm lyse BD Biosciences Oxford, UK 
Bovine gelatin Sigma Cambridgeshire, UK 
Chromium 51 Perkin Elmer Cambridgeshire, UK 
Dextran 40 Fresenius Kabi Barcelona, Spain 
Dimethylsulfoxide (DMSO) Sigma Poole, UK 
DNase Merck KGaA Darmstadt, Germany 
Ethanolamine Sigma Cambridgeshire, UK 
Ethylenediaminetetraacetic acid 
(EDTA) 0.5M ultra pure pH 8.0 
Life Technologies Paisley, UK 
Ficoll-Paque PLUS GE Healthcare Uppsala, Sweden 
GlutaMAX Life Technologies Paisley, UK 
GolgiStopTM BD Biosciences Oxford, UK 
Heparin sodium 1000 IU/mL Sigma Cambridgeshire, UK 
Hydrocortisone Sigma Dorset, UK 
Ionomycin (Iono) Sigma Cambridgeshire, UK 
L-Glutamine 1640 Lonza Verviers, Belgium 
Lympholyte VH BIO LTD. Gateshead, UK 
Magnesium chloride Sigma Poole, UK 
Penicillin and streptomycin (Pen-Strep) Lonza Verviers, Belgium 
Perm/fix buffer BD Biosciences Oxford, UK 
Phorbol myristate acetate (PMA) Sigma Cambridgeshire, UK 
PBS10X Lonza Verviers, Belgium 
Pulmozyme Roche Basil, Switzerland 
Sodium selenite Sigma Cambridgeshire, UK 
Sterile water Baxter Zurich, Switzerland 
Trisodium citrate Sigma Poole, UK 
Triton 100X VWR International Leicestershire, UK 
Trypan blue (0.4%) Sigma Poole, UK 
Trypsin (0.25%) with EDTA Life Technologies Paisley, UK 
Tween-20 Sigma Poole, UK 
-mercaptoethanol  Life Technologies Paisley, UK 
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Buffer/Media Composition 
10X Phosphate buffered saline (PBS) 1X PBS in distilled water 
Blocking buffer 10 % mouse serum in 1X PBS 
Complete Media RPMI 1640, 5 M, 10 % v/v FBS, 1 % 
Pen-Strep 
Degranulation assay staining buffer  1X PBS, 2 % FBS, 2 mM EDTA 
ELISA wash buffer 1X PBS, 0.05 % Tween-20 
FACS labelling buffer 1X PBS, 5 % FBS 
Freezing solution 90 % FBS, 10 % DMSO 
MACS labelling buffer 1 % BSA, 2mM EDTA, 1X PBS 
Thawing buffer 83.1 % Dextran 40, 5 % FBS, 6.3 % 
sodium citrate, 50 mM MgCl2 and 1000 
IU/mL DNAse 
Transport Media 0.05 M -mercaptoethanol, 0.63 % 
Trisodium citrate 
Table 2.5. Buffers. 
 
The plastics used throughout the present work can be found in table 2.6. 
Material Provider Location 
1 mL syringe BD Plastipack Madrid, Spain 
5 mL polypropylene 
round bottom tube 
BD Biosciences Erembodegen, Belgium 
Blunt fill needle 21G BD Biosciences Erembodegen, Belgium 
Cell strainer 40 M 
nylon 
BD Falcon Erembodegen, Belgium 
Cryotube vials (1.8 mL) 
foot round 
Nunc Roskilde, Denmark 
Falcon tubes (15 mL and 
50 mL) 
Sarstedt Numbrecht, Germany 
LS columns Miltenyi Biotec Bergisch Gladbach, 
Germany 
MD columns Miltenyi Biotec Bergisch Gladbach, 
Germany 
Ministart sterile filter Sartorius Stedim Biotech Munich, Germany 
Pasteur pipettes Fisher Loughborough, UK 
Serological pipettes (5, 
10 and 25 mL) 
Nunc Roskilde, Denmark 
Sharp fill needle 21G BD Biosciences Erembodegen, Belgium 
Tissue culture flasks (25, 
75 and 150 cm2) 
Sarstedt Numbrecht, Germany 
U-bottom 96-well plates Sarstedt Numbrecht, Germany 
V-bottom 96-well plates Sarstedt Numbrecht, Germany 
Table 2.6. Plastics. 
 
The cytokines used for cell differentiation and expansion can be found in table 2.7. 
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Cytokine Provider Location 
Fms-related tyrosine 
kinase 3 (FLT-3) 
ProSpec Israel 
Interleukin-2 (IL-2) ProSpec Israel 
Interleukin-3 (IL-3) ProSpec Israel 
Interkeukin-7 (IL-7) ProSpec Israel 
Interkeukin-12 (IL-12) ProSpec Israel 
Interleukin-15 (IL-15) ProSpec Israel 
Stem Cell Factor (SCF) ProSpec Israel 
Table 2.7. Cytokines. 
 
The antibodies used throughout this work including clone, fluorochrome and dilution 
can be seen in table 2.8.  
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Antibody Company Catalogue 
number 
Clone Isotype  Description 
Antibody Company Catalogue 
number 
Clone Isotype  Dilution Description 
Anti-CD16 BioLegend 302014 3G8 IgG1, κ 1/10 Activating receptor block 
Anti-CD178 (FasL) BioLegend 306408 NOK-1 IgG1, κ 1/10 Death receptor block 
Anti-CD253 (TRAIL) BioLegend 308207 RIK-2 IgG1, κ 1/10 Death receptor block 
Anti-CD314 (NKG2D) BioLegend 320809 MOPC-21 IgG1, κ 1/10 Activating receptor block 
BCL-2 FITC eBioscience BMS1028FI BCL2/100 IgG1, κ 1/10 Apoptotic regulation 
CCR5-PE R&D Systems 45531 45531 IgG2b, κ 1/10 Chemokine receptor 
CCR6-PE R&D Systems 53103 53103 IgG2b, κ 1/10 Chemokine receptor 
CCR7-PeCy7 BD Bioscience 557734 3D12 IgG2a, κ 1/10 Chemokine receptor 
CD107a-FITC BD Bioscience 555800 H4A3 IgG1, κ 1/40 Degranulation  
CD11a (LFA-1)-FITC BD Bioscience 555383 HI111 IgG1, κ 1/100 Integrin 
CD133-PE Miltenyi 130-090-853 293C3  IgG2b, κ 1/100 Stem cell marker 
CD159a (NKG2A)-PE Beckman Coulter IM3291U Z199 IgG2b, κ 1/20 Inhibitory receptor 
CD16-Alexa fluor 700 BD Bioscience 560713 3G8 IgG1, κ 1/20 Activating receptor 
CD226 (DNAM-1)- FITC BD Bioscience 559788 DX11 IgG1, κ 1/25 Adhesion marker 
CD244 (2B4)-APC eBiosciences 16-2449 PP35  IgG1, κ 1/10 Activating/inhibitory receptor 
CD253 (TRAIL)- BV 421 BD Bioscience 564243 RIK-2 IgG1, κ 1/20 Death receptor 
CD3-PerCP BD Bioscience  347344 SK7 IgG1, κ 1/20 T cell marker 
CD314 (NKG2D)-PeCy7 BD Bioscience 562365 ID11 IgG1, κ 1/20 Activating receptor 
CD335 (NKp46)-PeCy7 BD Bioscience 562101 9E2/NKp46 IgG1, κ 1/20 Activating receptor 
CD336 (NKp44)-APC Biolegend 325110 P44-8 IgG1, κ 1/10 Activating receptor 
CD337 (NKp30)-BV421 BD Bioscience 562285 P30-15 IgG1, κ 1/50 Activating receptor 
CD34-PeCy7 BD Bioscience 348811 CE/IVD IgG1, κ 1/50 Stem cell marker 
CD45-Alexa fluor 700 BD Bioscience 555485 HI30 IgG1, κ 1/20 Differentiation 
CD48-FITC BD Bioscience 555759 TÜ145 IgM, κ 1/10 Activating receptor 
CD49d-PeCy5 BD Bioscience 555502 9F10 IgG1, κ 1/50 Integrin 
CD56 PeCy5 BD Bioscience 557747 B159 IgG1, κ 1/10 NK cell marker 
CD56-APC BD Bioscience 555518 B159 IgG1, κ 1/10 NK cell marker 
CD56-PeCy7 BD Bioscience 555516 B159 IgG1, κ 1/20 NK cell marker 
CD57-APC BD Biocience 560845 NK-1 IgM, κ 1/10 Maturation marker 
CD62-L-AF647 BD Bioscience 565062 SKI11 IgG2a, κ  1/50 Adhesion marker 
CD69-Alexa fluor 700 BD Bioscience 560739 FN50 IgG1, κ 1/10 Activation marker 
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CXCR1-PE R&D Systems FAB330P 42705 IgG2a, κ 1/10 Chemokine receptor 
CXCR4-APC R&D Systems FAB170P 12G5 IgG2a, κ 1/10 Chemokine receptor 
CXCR7-PE R&D Systems FAB42271P 358426 IgG2a, κ 1/50 Chemokine receptor 
Granzyme B-FITC BD Bioscience 560211 GB11 IgG1, κ 1/10 Cytotoxicity 
HLA DR-PeCy7 BD Bioscience 555811 G46-6 IgG2a, κ 1/20 MHC II receptor 
IDO-1-PE eBioscience 12-9477-41 eyedio IgG1, κ 1/10 Immunomodulatory 
IFN-γ-FITC BD Bioscience 554551 4S.B3 IgG1, κ 1/50 Immunomodulatory  
IgG1 Isotype BD Bioscience 554721 107.3 IgG1, κ 1/10 IgG1 control 
IL-12Rβ1 (CD212)-APC BD Bioscience 558708 2.4 E6 IgG1, κ 1/10 Interleukin receptor 
IL-15Rα-PE eBiosciences 12-7159-42 eBioJM7A4 IgG2, β 1/20 Interleukin receptor 
IL-18R-FITC eBiosciences 11-7183-42 H44 IgG1, κ 1/10 Interleukin receptor 
IL-1-PE eBioscience 12-7018-41 CRM56 IgG1 1/10 Inflammation 
IL-2Rα (CD25)-BV 510 BD Bioscience 563352 MA251 IgG1, κ 1/50 Interleukin receptor 
Integrin β7-FITC eBiosciences 11-5867-42 FIB504 IgG2a, κ 1/50 Integrin 
NKG2C-PE R&D Systems FAB138P 134591 IgG1, κ 1/25 Activating receptor 
Pan KIR-FITC R & D systems Fab1848F 180704 IgG2, β 1/20 Activating/inhibitory receptor 
TO-PRO-3 Life technologies T3605 - - 1/10 Viability dye 
       
Table 2.8. Monoclonal antibodies. 
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2.1.1. Blood donors 
 
2.1.1.1. Peripheral blood 
 
Fresh peripheral blood (PB) samples were obtained from healthy donors, upon 
written informed consent. The study had full ethical approval from the Anthony 
Nolan and Royal Free Hospital Research Ethics Committee (Research Ethics 
Committee reference HC71/10). Blood was collected into commercial 10 mL tubes 
containing heparin (BD Vacutainer).  
 
2.1.1.2. Umbilical cord blood 
 
CB samples were obtained after normal full-term delivery from the Anthony Nolan 
Cord Blood Bank Nottingham, UK, with written consent from the mother (Research 
Ethics Committee reference 10/H0405/27). Samples were obtained into a CB 
donation bag containing citrate-phosphate-dextrose anticoagulant within 24 h using 
routine banking procedures. 
 
2.1.2. Cell lines  
 
2.1.2.1. Acute myeloid leukaemia samples  
 
Prof. M. Lowdell (UCL) kindly supplied PB samples from patients with presentation 
of Acute Myeloid Leukaemia (AML) for cytotoxicity assays. AML sample 
classification can be found in table 2. 9. All samples were obtained with written 
informed consent for research into “innate immunity to leukaemia” from the Royal 
Free Hospital Research Ethics Committee. The study had full ethical approval from 
the Royal Free Hospital Research Ethics Committee. 
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Sample ID Classification 
310 Pres AML M3 
285 Rel AML 
053 Rel  AML 
304 Pres AML 
302 Pres AML M1 
291 Pres AML 
290 Pres AML M3 
284 Pre-chemo AML 
206 AML M4 
Table 2.9. AML Classifications. 
 
2.1.2.2. A478 
Renal cell carcinoma established from an 18-year-old Japanese female. The cells 
grow adherently at 37 oC, 5 % CO2 and 96 % humidity in complete media. 
 
2.1.2.3. CTV-1 
 
CTV1 is a human T cell acute lymphoblastic leukaemia (T-ALL). The cell line 
grows as single or clustered cells in suspension at 37 oC, 5 % CO2 and 96 % 
humidity in complete media.  
 
2.1.2.4. EL08.1D2 cells 
 
EL08.1D2 is an embryonic liver cell line that is cultured on gelatin covered plates at 
32 oC with 5 % CO2. Culture media consists of 40.5 % -MEM, 50 % MyeloCult, 
7.5 % FBS with 50 M -Mercaptoethanol, 2 mM GlutaMAX, 100 U/mL penicillin, 
100 U/mL streptomycin, 10-6 M hydrocortisone and 20 % 0.2 nm filtered conditioned 
media from previous EL08.1D2 cultures. This cell line has been proven to support 
the generation of NK cells from human haematopoietic precursors (Grzywacz et al., 
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2011, Abdulrazzak et al., 2010). This cell line was kindly provided by Dr. Robert 
Oostedrop. 
 
2.1.2.5. HT-29 
 
Colorectal adenocarcinoma cell line established from the primary tumour of a 44 
year old female. The cells grow adherently at 37 oC, 5 % CO2 and 96 % humidity in 
complete media. 
 
2.1.2.6. K562 cells 
 
K562 cells are a chronic myeloid leukaemia (CML) cell line (Lozzio and Lozzio, 
1975) that is grown in a single cell suspension at 37 oC, 5 % CO2 and 96 % humidity 
in complete media. The cell line is sensitive to NK cell-mediated killing due to the 
absence of MHC class I antigens and the high expression of NKG2D ligands, which 
leads to strong activation of NK cells (Bae et al., 2012). 
 
2.1.2.7. GFP-K562 cells 
 
1 x 106 K562 cells were transfected with the lentivirus pHRSinCpptSEW kindly 
supplied by Dr. Michael Blundell (UCL, Institute of Child Health) at a concentration 
of 1 x 109/200 L in complete media. 48h post-transfection, the expression of EGFP 
was analysed via flow cytometry. To ensure the EGFP gene was stably expressed the 
media was replenished on a regular basis before sorting for the EGFP+ population 
using the FACSAria I cell sorter (BD Biosciences, US).  
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2.1.2.8. MCF-7 
 
MCF-7 is a breast adenocarcinoma cell line that grows adherently at 37 oC, 5 % CO2 
and 96 % humidity in complete media. 
 
2.1.2.9. Melanoma cell lines 
 
Two cells lines established from primary (MELHO) and metastatic (1520) melanoma 
were kindly supplied by Prof. Francesco Colucci (Cambridge University). His group 
cultured the cells to obtain both susceptible and resistant fractions to BRAF 
inhibitors. All cell lines grow adherently at 37 oC, 5 % CO2 and 96 % humidity in 
complete media. 
 
2.1.2.10. RAJI 
 
Burkitt lymphoma cell line that was established from an 11 year old male (Pulvertaft, 
1964). It is one of the prototypical NK cell-resistant cell lines and grows as single 
cells or clustered in suspension at 37 oC, 5 % CO2 and 96 % humidity in complete 
media.  
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2.2. Methods 
 
2.2.1. Molecular biology 
 
2.2.1.1. RNA extraction 
 
The RNeasy Mini Kit was used to extract RNA according to manufacturer’s 
guidelines. RNaseZap was used for cleaning pipettes and work surfaces. RNA 
samples were tested for quality and quantified using NanoDrop-1000 
Spectrophotometer. 
 
2.2.1.2. Complementary DNA 
 
The reagents used for the reverse transcription reaction are listed in table 2.10. 
 
 
Reagent Provider Location 
dNTPs Life Technologies Paisley, UK 
DTT 0.1M Life Technologies Paisley, UK 
Random primers 500 g/mL Promega Southampton, UK 
Recombinant RNA sin inhibitor Promega Southampton, UK 
RNAase/DNAse free water Life Technologies Paisley, UK 
RNase zap Life Technologies Paisley, UK 
SuperScript II Reverse Transcriptase Life Technologies Paisley, UK 
Table 2.10. Reverse transcription reagents. 
 
 
Complimentary DNA (cDNA) was produced by incubating 2 L RNA at 100 ng/L 
with 7 L of sterile water, 2 L random primers at 600 g/mL and 1 L 25 nM 
dNTPs in a Mastercycle thermocycler. The reaction was first heated at 65 oC for 5 
min, before being placed on ice for 5 min. Then, 4 L of buffer 5X, 2 L of DTT 
(100 mM) and 1 L of recombinant RNasin ribonuclease inhibitor 40 U/L was 
added. The mixture was then incubated at 25 oC for 10 min, followed by 42 oC for 2 
min. Next 1 L Superscript III Reverse transcriptase 200 IU/L was added and the 
mixture further incubated at 42 oC for 50 min then 70 oC for 15 min. Samples could 
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then be stored at -20 oC (maximum one week). Prior to use samples were re-
suspended in 40 L sterile water. 
 
2.2.1.3. Real time-PCR 
 
Precision 2X real time PCR master mix with low ROX and SYBR green was used 
for all real time PCR reactions. The reference gene kit geNorm was used for optimal 
determination of housekeeping genes for all reactions. The selected genes included 
ATP synthase 5B (ATP5B), unbiquitin C (UBC) and topoisomerase 1 (TOP 1). 
Primers were either selected from published studies or designed via NCBI (table 
2.9). All reactions were performed using the following PCR programme: 2 min 50 
oC, 10 min 95 oC, and 50 cycles of 15 seconds 95 oC and 1 min 60 oC. Additionally a 
dissociation stage was added of 1 cycle at 95 oC for 15 seconds, 60 oC for 1 min, 95 
oC for 15 seconds and 60 oC for 15 seconds was added at the end of each PCR 
reaction to determine specificity of amplification. Results are presented as target 
gene expression relative to housekeeping gene expression therefore the higher the 
ratio the lower the amount of messenger RNA (mRNA) of the gene of interest. 
 
The reactions were carried out in a 96 well hard shell PCR plate form BioRad with 
optical adhesive films from Applied Biosystems. The real time PCR analysis was 
performed using CFX96 Real time PCR system. 
  
2.2.1.4. Primers 
 
All primers were obtained from Sigma-Aldrich (US) and sequences can be found in 
table 2.11. 
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Primer Sequence Conc 
(nM) 
Source 
EOMES 
F: 5’-ACTGGTTCCCACTGGATGAG-3’ 
R: 5’-CCACGCCATCCTCTGTAACT-3’ 
300nm (Hertoghs et 
al., 2010) 
T-BET 
F: 5’-GGATGCGCCAGGAAGTTTCA-3’ 
R: 5’-CTCTGGCTCTCCGTCGTTCA-3’ 
300nm (Pinho et al., 
2012) 
Table 2.11. Primer sequences. 
 
2.2.2. Mononuclear cell separation 
 
Cord blood mononuclear cells (CBMCs) were obtained from heparinised CB mixed 
with an equal volume of transport media at room temperature (RT). 35 mL of diluted 
whole blood was layered onto 15 mL of Ficoll-Paque PLUS. The mononuclear layer 
was separated via density gradient centrifugation at 2000 rpm for 30 min at RT 
without break. Where healthy controls were required peripheral blood mononuclear 
cells (PBMCs) were obtained from heparinised PB separated via density 
centrifugation at 1800 rpm for 25 min at RT without break where 25 mL of diluted 
whole blood was layered onto 25 mL of Lympholyte. 
 
2.2.3. Freezing and thawing cells 
 
Isolated CD34+ cells were re-suspended in FBS + 10 % DMSO on ice and frozen at a 
concentration of 1 x 106 cells/mL. Differentiated NK cells were re-suspended in AB 
serum + 10 % DMSO at 1 x 106 and 5 x 106 cells/mL. All cells were kept at -80 oC in 
a CoolCell freezing container for 12 h before transfer to liquid nitrogen. 
 
Frozen cells were thawed in a 37 oC water bath before transfer to 1 mL of thawing 
mix and the addition of 10 mL of warm complete media. 
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2.2.4. Cell isolations 
 
CD34+ CB cells were isolated using the Miltenyi Biotec CD34 microbead kit. A 
modified protocol by Jaatinen and Laine (Jaatinen and Laine, 2007) was 
implemented involving two labelling steps to improve purity. Here the 
manufacturer’s instructions are followed before an additional labelling step with 25 
μL FcR blocking reagent and 25 μL microbeads for 15 min at 4 oC afterwards the 
cells are passed through an MS column. All solutions were kept at 4 oC to avoid 
antibody dissociation and the labelling buffer was supplemented with 20 % AB 
serum, which prevents non-specific binding. The remaining procedure was 
performed according to the manufacturers’ protocol. The isolation purities were 
analysed following the International Society of Hematotherapy and Graft 
Engineering (ISHAGE) guidelines (Barnett et al., 1999) as shown in Figure 2.1 The 
mean purity (%) ± SD of all isolations carried out was 91.27  4.28%. 
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Figure 2.1. Purity of CD34+ isolations from CB. Representative flow cytometry 
plots showing (A) Lymphocyte gate (B) Gating on all CD45+ cells (B) and viability 
staining with DAPI (C) Gating for CD34+ vs. SSC (D) Gating for CD45dim (E). Final 
purity calculated as percentage of double positive CD133+CD34+ population (F) 
divided by total events of live cells. 
 
Frozen CD34+ PBSC samples were kindly supplied by Kwee Yong (UCL, Cancer 
Institute). 
 
NK cells were isolated using the Miltenyi Biotec NK cell negative selection kit. The 
manufacturer’s instructions were followed throughout the isolation except the cells 
were re-suspended in 5 mL instead of 500 L before being passed through LS 
columns and washing steps were performed with 2 x 7 mL of MACS buffer. Purity 
of the cells was determined by gating on the live CD56+CD3- populations as shown 
in Figure 2.2. The mean purity (%) ± SD of all isolations carried out was 78.2 ± 5.43 
for PBNK cells and 80.4 ± 6.21 for CBNK cells. The mean purity (%) ± SD of 
CBCD34+-NK cells was 94.2 ± 4.15. 
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Figure 2.2. Purity of NK cell isolations from PB, CB and CBCD34+-NK cells. 
Representative flow cytometry plots showing NK cells isolated from PBMCs (A), 
CBMCs (B) and CBCD34+-NK cells (C). Lymphocytes gated according to forward 
versus side scatter and then live NK cells gated based on the expression of CD56 and 
absence of CD3. 
 
2.2.5. Culture conditions for NK cell differentiation 
 
The basic culture media for NK cell differentiation consisted of a 2:1 ratio of DMEM 
high glucose with L-glutamine and Ham’s F12 medium supplemented with 50 M -
Mercaptoethanol, 50 M ethanolamine, 20 mg/L ascorbic acid, 50 g/L sodium 
selenite, 1 % penicillin & streptomycin and 20 % heat-inactivated human AB serum. 
Cultures were hemi-depleted on a weekly basis with medium containing the 
following cytokines: for the first three weeks 10 ng/mL IL-15, 20 ng/mL IL-7, 20 
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ng/mL c-kit ligand, 10 ng/mL Flt3 ligand and 5 ng/mL IL-3 (week 1 only) and for 
the final two weeks 50 ng/mL IL-15 only. 
 
2.2.6. Flow cytometry 
 
Samples were run using the BD LSR Fortessa (US) and data analysed by FlowJo 
version vX0.7. 
 
2.2.7. Surface Staining 
 
Cells were incubated in the dark at 4 oC for 10 min with fluorochrome-conjugated 
mAbs, washed and re-suspended in FACS buffer. Data was acquired using a BD 
Biosciences LSR Fortessa and analysed using Flowjo vX0.7 software. 
 
2.2.8. Cellular stimulation 
 
Cells were incubated without stimulus, with K562 cells at a ratio of 1:1 or PMA (100 
ng/mL) and Ionomycin (10 ng/mL) at 37 oC, 5 % CO2 and 96 % humidity 96 well U 
bottomed plates. 
 
2.2.9. Intracellular staining 
 
After stimulation for 1 h GolgiStopTM was added to each well as per manufacturer’s 
instructions and incubated for a further 4 h. Cells were blocked with 100 L 10 % 
mouse serum to prevent non-specific binding of the Fc receptors before surface 
staining with anti-CD56, -CD16 and -CD3. Permeabilisation and fixation was then 
carried out using the BD Cytofix/Cytoperm Plus kit. Cells were then stained with 
antibody or appropriate isotype control before analysis by flow cytometry. 
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2.2.10. CD107a degranulation assay 
 
After stimulation for 2 h cells were blocked with 100 L 10 % mouse serum in 
staining buffer for 10 min at RT before surface staining with anti-CD56, -CD16 and -
CD3. The cells were then washed and stained with anti-CD107a or appropriate 
isotype control for 45 min before analysis by flow cytometry. 
 
2.2.11. Blocking 
 
Death receptors were blocked to analyse their involvement in killing by primed NK 
cells. Cells were incubated for 30 min at RT with optimised blocking antibody 
concentration alongside isotype control. Overnight incubation with CTV-1 lysate 
followed before assessing function by a 4h in vitro cytotoxicity assay against NK cell 
resistant RAJI cells. 
 
2.2.12. CFSE 
 
NK cells (1 x 106) were labelled with 2 M Celltrace CFSE Cell Proliferation kit 
according to the manufacturer’s protocol. The stained cells were then re-suspended, 
transferred to 96 well round bottomed plates and stimulated with 1 ng/mL IL-15 and 
either 200 IU or 1000 IU IL-2. Proliferation was analysed by flow cytometry at days 
0, 2, 5 and 7. 
 
2.2.13. NK cell priming 
 
NK cell priming was performed using a lysate produced from CTV-1 cells that were 
kindly supplied by Prof M. Lowdell (UCL). The lysate was produced by 3 freeze 
thaw cycles at -80 oC and 37 oC respectively. Genomic DNA was removed by the 
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addition of 3 g of pulmozyme per 5 x 106 of cells. NK cells and CTV-1 lysate were 
incubated at 37 oC, 5% CO2 and 96 % humidity overnight at an NK cell-to-lysate 
ratio of 1:2 in complete media (North et al., 2007). 
 
2.2.14. Flow cytometry based cytotoxicity assay 
 
Target cells were labelled with PKH26 Red Fluorescent Cell Linker Kit as per 
manufacturer’s instructions. Target and effector cells were seeded in FACS tubes at a 
target-to-effector ratio of 1:5 in 400 L in triplicate and incubated at 37 oC, 5 % CO2 
and 96 % humidity for 4 h. Samples were labelled with the viability dye TO-PRO-3 
iodide and analysed by flow cytometry. An example of the gating strategy can be 
seen in figure 2.3. 
 
Figure 2.3. Representative flow cytometry plots of in vitro killing assay. Gate on 
forward/side scatter before selecting PKH26+ population. Cytotoxicity then assessed 
by viability stain. A) in vitro K562 cytotoxicity assay B) Patient AML blast 
cytotoxicity assay. 
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2.2.15. In vivo killing assays 
 
Sub-lethally irradiated adult NSG mice (8 weeks old) were infused by intravenous 
injection 4 h after conditioning with 1 x 106 GFP-K562 cells, or PKH26 labelled 
patient AML blasts. 24 h later they were injected intravenously with 20 x 106 
CBCD34+-NK cells for the K562 assay or 20 x 106 resting or primed CBCD34+-NK 
cell for the AML assay. A triplicate of non-injected control mice was carried for each 
experiment. After 24 h the BM, lungs, liver and spleen were harvested. Each sample 
was then passed through a cell strainer to make a cell suspension and red blood cell 
lysis was performed. The cells were then surface stained with anti-CD56, anti-CD3 
and analysed by FACS. All experiments were performed in agreement with Home 
Office regulations (project license 80/1293). 
 
2.2.16.  51Cr release assay 
 
The target K562 cell line (1 x 106) was labelled with 100 Ci .51Cr for 4 h at 37 oC, 5 
% CO2 and 96 % humidity before washing twice with 1X PBS. Effector cells were 
plated at an effector-to-target ratio of 1:1, 5:1 and 10:1 in triplicate. Maximum 
chromium release was determined by incubating targets with 1 % Triton X-100 in 
1X PBS and minimum chromium release was determined by incubation with RPMI 
+ 10 % FBS. Following a 4 h co-culture at 37 oC, the cells were pelleted by 
centrifugation and then 30 L of supernatant was collected per sample and left to dry 
overnight. To assess chromium release, 30 L of Scintillation solution was added to 
each well and a Wallac 1450 Micro beta liquid scintillation counter was used to read 
the plates. Percentage of specific lysis = (experimental release – spontaneous 
release)/(maximum release – spontaneous release) x 100. 
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2.2.17. Telomere length analysis 
 
To investigate the cell “age” telomere length analysis was performed in line with 
manufacturer’s instructions using the telomere PNA kit/FITC. Denatured samples 
and control cells are incubated with a fluorescein-conjugated peptide nucleic acid 
(PNA) probe. After incubation with a DNA staining solution cells are analysed by 
flow cytometry. Telomere length is then calculated relative to the control cells. 
 
2.2.18. Statistics 
 
Statistical analyses were performed using GraphPad Prism v.6 software. Statistical 
analysis was carried out using the Mann Whitney test. Results are presented as 
median  range. Corrected p values  0.05 (*), 0.01 (**) and  0.001 (***) were 
considered statistically significant. 
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ifferentiated in vitro from CBCD34+ Cells 
  
Chapter 3 
 
The Function and Phenotype of 
NK Cells Differentiated in vitro 
from CBCD34+ Cells 
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3.1 Introduction 
 
NK cells function by two key mechanisms. They are able to kill target cells via 
secretion of granules containing perforin/granzymes or via activation of death 
receptor pathways such as TRAIL or FAS/FASL. NK cells can also produce 
cytokines such as IFN, TNF and GM-CSF (Vivier et al., 2004). It has been 
reported that PBNK cells and CBNK cells have a distinct function from one another 
(Cooper, 2001). CBNK cell populations are more naïve and heterogeneous compared 
to their PBNK cell counterparts (Hoshina et al., 1999, Tanaka et al., 2003) and 
resting CD56dim PBNK cells have been shown to be substantially more cytotoxic 
than CD56dim CBNK cells (Luevano et al., 2012). This could be attributed to the 
distinct phenotype of CBNK cells that have a higher expression of inhibitory 
receptors and lower expression of adhesion markers (Wang et al., 2007, Tanaka et 
al., 2003). Full function, comparable to that of PBNK cells can however be rescued 
by cytokine activation (Alnabhan et al., 2014). These fundamental differences may 
therefore imply that NK cells differentiated from CB CD34+ cells may also have an 
alternative phenotypic and functional profile to PBNK cells and CBNK cells.  
 
It has previously been shown that frozen CB CD34+ cells can be used to produce 
high numbers of functional NK cells (Luevano et al., 2014). Here a thorough 
characterisation of the functional properties of CBCD34+-NK cells was performed 
clearly defining cytotoxicity against K562 cells, intracellular IFN-, granzyme B and 
perforin expression, degranulation and cytokine release. A functional comparison 
with freshly isolated PBNK cells and CBNK cells however has not yet been carried 
out. It is therefore important to identify how the function of CBCD34+-NK cells 
compares to that of other cell sources. If their function is equivalent to other cell 
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sources they could offer an additional option for clinical application. If a difference 
is observed this may imply that prior activation or treatment prior to infusion may be 
necessary. The next logical step in clinical translation of NK cell immunotherapy is 
therefore elucidating how CBCD34+-NK cell phenotype and function compares to 
that of freshly isolated PBNK cells and CBNK cells.  
 
A majority of previous studies assessing NK cell function of cells differentiated in 
vitro focus mainly on using the standard Cr51 release assay against K562 cells 
(Luevano et al., 2014, Spanholtz et al., 2010, Woll et al., 2005). The in vitro 
proliferation of the cells after the culture period is often an essential function that is 
ignored. In order for an immunotherapy to target a malignancy in vivo it is 
imperative that the cells can further proliferate and persist. The long-term culture of 
lymphocytes has shown a poor proliferation profile (Cheng et al., 2013) in a clinical 
setting implying that constant cytokine stimulation results in a senescent cell 
population and resultant poor cytotoxic effect in vivo. IL-2 and IL-15 are key 
cytokines involved in the activation, differentiation and proliferation of NK cells 
(Liu et al., 2000, Yu et al., 2000, Fehniger et al., 2002). It is therefore important to 
assess how IL-2 and IL-15 stimulation effects NK cell proliferation at the end of the 
culture period. If CBCD34+-NK cells cannot proliferate following additional 
cytokine stimulation then it will be unlikely that CBCD34+-NK cells will be able to 
proliferate, persist and target malignancies once infused into the patient. 
 
The differentiation of a healthy NK cell population is imperative to the development 
of a clinically effective therapy. Surprisingly literature studying the differentiation 
markers on a molecular and cellular level of NK cells is limited. EOMES and TBET 
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have been identified as key markers of lymphocyte exhaustion and their down 
regulation is associated with poor NK cell cytotoxicity against tumour cells 
(Simonetta et al., 2015). Telomere length shortening occurs in vitro with every cell 
division and in vivo with age, telomere length can thus be an indicator of the residual 
life span of normal somatic cells (Mariani et al., 2003). Further the terminal 
differentiation marker CD57 can identify the life stage of NK cells as the expression 
of CD57 increases with age (Lopez-Verges et al., 2010). A fully functional yet 
younger cell profile would be more desirable for clinical application as an improved 
survival in vivo would likely be seen. 
 
Deficient expression of HLA class I molecules on AML cells (Elkins et al., 1984) 
make them an excellent target for cell mediated NK cell lysis. The GvL effect by NK 
cells could be used to prevent relapse post HSCT or as a therapy alone to eradicate 
residual leukaemic cells post chemotherapy. It has previously been shown that NK 
cells are capable of killing AML cells in vitro (Brune et al., 1996) and further a 
clinical trial carried out by Dolstra and colleagues (Dolstra et al., 2015) using NK 
cells differentiated from CB has shown they could induce and sustain CR in elderly 
AML patients. Assessing the ability of CBCD34+-NK cells to target AML blasts in 
comparison to PBNK cells is therefore an additional function that would further 
characterise the suitability of applying CBCD34+-NK cell therapy to the clinic. 
 
In this chapter the effect of cytokine stimulation on proliferation of CBCD34+-NK 
cells is compared to that of resting PBNK cells and CBNK cells. Further assessments 
of key molecular and cellular markers of differentiation are performed to compare 
the cell age of CBCD34+-NK cells in comparison to NK cell controls. In addition it 
was identified if CBCD34+-NK cells could kill the K562 cell line in vivo as in vivo 
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function is fundamental for clinical trial approval. Finally the ability of CBCD34+-
NK cells to target patient AML blasts in vitro was studied in comparison to PBNK 
cell controls. The function of CBCD34+-NK cells in response to these stimuli will 
help to determine if NK cells differentiated from CBCD34+ cells demonstrate 
equivalent functions as PBNK cells and CBNK cells.
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3.2 Results 
3.2.1. Natural Killer cells differentiated in vitro can respond to the same 
concentration of IL-2 as PBNK cells 
 
Due to their immature phenotype it has previously been shown that CBNK cells 
require a significantly higher concentration of IL-2 to further proliferate in vitro in 
comparison to PBNK cells (Luevano et al., 2012). Therefore not only must it be 
identified if CBCD34+-NK cells can further proliferate but also what concentration 
of IL-2 is required to achieve this stimulation. The response of CBCD34+-NK cells 
was therefore tested against 200 IU and 1000 IU of IL-2, the optimum concentration 
to activate PBNK and CBNK cells respectively. Proliferation was then assessed by 
CFSE analysis, here cell divisions are assessed by measuring the decrease in 
fluorescence over time via flow cytometry (Quah and Parish, 2010). It can be seen 
that NK cells differentiated in vitro are capable of responding to both concentrations 
of IL-2 as shown by CFSE dilution for each condition tested (figure 3.1A). Further 
there is no difference observed in the degree of proliferation as measured by the MFI 
of CFSE where at day 30 the MFI after stimulation with 200 IU was 26353 (21254 – 
36139) in comparison to 27188 (20857 – 36185) after stimulation with 1000 IU and 
at D35 the MFI was 8808 (1642 – 9936) after stimulation with 200 IU and 6311 
(5146 – 7140) after stimulation with 1000 IU (figure 3.1B). CBCD34+-NK cells can 
therefore proliferate in vitro after stimulation with the same concentration of IL-2 as 
PBNK cells hereafter 200 IU of IL-2 was used in this work to stimulate CBCD34+-
NK cells. 
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Figure 3.1. Identifying the IL-2 concentration required for CBCD34+-NK cell 
proliferation. CFSE was used to analysis the proliferation of CBCD34+-NK cells 
after stimulation with 200 (n = 3) or 1000 IU (n = 3) of IL-2. A) Representative 
gating strategy at D33 B) Representative FACS plot of CFSE dilution where the red 
line represents day 30, blue line day 33 and orange line day 35. C) The median MFI 
CFSE ( range) at day 30, day 33 and day 35 of culture corresponding to day 2, 5 
and 7 post-activation by CBCD34+-NK cells is shown. 
 
3.2.2. Natural Killer cells differentiated in vitro can further proliferate following 
additional cytokine stimulation 
 
It is a common finding that after long-term exposure to cytokines in vitro 
lymphocytes can start to demonstrate a senescent cell profile and fail to respond to 
additional stimulation and show poor proliferation (Childs and Berg, 2013). This is 
the result of the down-regulation of cytokine receptors during long-term proliferation 
in vitro (Hedfors and Brinchmann, 2003). If NK cells fail to respond to cytokine 
stimulation in vitro it is unlikely that they would be able to mount an immune 
response against cancer cells in vivo as they would be unable to further proliferate 
once infused into the patient and persist. It is therefore not only necessary to identify 
 97 
if CBCD34+-NK cells can respond to further cytokine stimulation but also that they 
are capable of responding to the same degree as PBNK and CBNK cell controls. If 
their proliferative ability was inferior to other NK cell sources they would unlikely 
be a successful cell product for clinical application. Therefore to identify if 
CBCD34+-NK cells can further respond to additional cytokine stimulation 
proliferation was assessed by CFSE analysis after stimulation with two cytokines IL-
2 and IL-15. The response of CBCD34+-NK cells to these cytokines was compared 
to the response of PBNK cells and CBNK cells as controls. IL-15 was also assessed 
in this study in addition to IL-2 as it is a key stimulator of NK cell differentiation and 
proliferation (Liu et al., 2000) and has also been identified as being superior at 
inducing activation and proliferation of CBNK cells in vitro (Alnabhan et al., 2014). 
 
Figure 3.2A shows that CBCD34+-NK cells are capable of further proliferation in 
response to IL-2 and IL-15 as shown by the decreased CFSE MFI. IL-2 stimulated 
NK cells had an MFI of 178838.5 (17006 – 19261) at day 30 that was significantly 
reduced to 9638.5 (7826 – 12232) at day 35 (p < 0.05) and IL-15 stimulated NK cells 
had an MFI of 17639 (16779 – 19287) at day 30 that was significantly reduced to 
9446 (7506 – 10732) at day 35 (p < 0.05). In addition the cells are able to 
demonstrate the same degree of proliferation as PBNK cells (Figure 3.2B) and 
CBNK cells (Figure 3.2C) and there is no significant difference in the level of 
response after NK cells of any source are stimulated with either IL-2 or IL-15. It can 
therefore be concluded that NK cells differentiated in vitro from CBCD34+ cells can 
respond to cytokines as proficiently as freshly isolated PBNK cells and CBNK cells.  
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Figure 3.2. The proliferation of CBCD34+ NK cells, PBNK cells and CBNK cells 
following additional cytokine stimulation in vitro. CFSE analysis was used to 
assess the proliferation of CBCD34+-NK cells (A), PBNK cells (B) and CBNK cells 
(C) after stimulation with 200 IU of IL-2 for CBCD34+ and PBNK cells and 1000 IU 
of IL-2 for CBNK cells or 20 ng/mL IL-15. Median MFI of CFSE (± range) 
CBCD34+-NK cells (n=4), PBNK cells (n=4) and CBNK cells (n=4) is shown.* p < 
0.05. 
 
3.2.3. NK cells differentiated in vitro have a longer telomere length than PBNK 
cells and CBNK cells 
 
Exhaustion and therefore reduced anti-tumour activity is associated with long-term in 
vitro culture of NK cells. It is therefore important to assess the levels of key 
differentiation markers of CBCD34+-NK cells and assess how those levels compare 
to resting PBNK and CBNK cells. EOMES and TBET are key molecular markers of 
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cellular exhaustion (Gill et al., 2012) and their down-regulation is associated with 
impaired cytotoxicity in vivo (Simonetta et al., 2015). Real time-PCR was therefore 
used to compare the expression of EOMES and TBET by resting CBCD34+-NK 
cells, PBNK cells and CBNK cells. Figure 3.3 shows that there was no significant 
difference observed in the expression of these markers where the relative expression 
of EOMES by CBCD34+-NK cells, PBNK cells or CBNK cells was 1.424 (1.357 - 
1.511), 1.324 (1.220 - 1.426) and 1.308 (1.205 - 1.371) respectively. Whilst the 
relative expression of TBET was 1.382 (1.326 - 1.449) for CBCD34+-NK cells, 
1.244 (1.209 - 1.326) for PBNK cells and 1.300 (1.226 – 1.335) for CBNK cells. 
Therefore CBCD34+-NK cells do not demonstrate an exhausted molecular phenotype 
as they show an equivalent expression of EOMES and TBET in comparison to 
resting PBNK cells and CBNK cells. 
 
Figure 3.3. How the expression of EOMES and TBET by CBCD34+ NK cells 
compares to PBNK cells and CBNK cells. EOMES and T-bet expression was 
analysed by RT-PCR. Median relative expression (± range) of CBCD34+-NK cells (n 
= 6), PBNK cells (n = 6) and CBNK cells (n = 6) is shown. 
 
Lymphocytes undergo a limited number of cell divisions in their lifetime ultimately 
entering a proliferative state called replicative senescence; telomere shortening has 
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therefore been identified as the measure that can identify cell age (Bodnar et al., 
1998). Telomere length is reduced as it moves closer to replicative senescence, 
therefore comparing the telomere length of CBCD34+-NK cells, PBNK cells and 
CBNK cells can give an accurate assessment of cell age. Figure 3.4 shows that 
CBCD34+-NK cells have a significantly longer relative telomere length in 
comparison to PBNK cells 17.44 % (12.11 - 22.05) vs 11.29 % (9.71 – 15.23) (p < 
0.05) and although no significance was observed, this trend was also seen with 
CBNK cells where the relative telomere length was 14.23 % (8.36 – 17.55). 
CBCD34+-NK cells therefore have a younger cell age than NK cells from other 
sources, this would imply an ability to survive and persist for longer in vivo.  
 
Figure 3.4. Comparative telomere length of CBCD34+ NK cells, PBNK cells and 
CBNK cells. A telomere PNA kit was used to analysis telomere length analysis. 
Median relative telomere length (± range) of CBCD34+-NK cells (n = 6), PBNK 
cells (n = 6) and CBNK cells (n = 6) is shown. ** p < 0.01. 
 
As well as being a marker for memory like NK cells (Lopez-Verges et al., 2011) 
CD57 is expressed at the last stage of maturation of NK cells and has been associated 
with cellular exhaustion (Lopez-Verges et al., 2010). The expression level of this 
marker therefore further characterises the life stage of the NK cells. It can be seen in 
figure 3.5 that the percentage expression of CD57 on PBNK cells, 54.65 % (42.4 – 
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74.0) was significantly higher than the expression observed on CBCD34+-NK cells, 
8.58 % (2.04 – 17.2) (p < 0.001) and CBNK cells, 28.4 % (18.8 – 40.3) (p < 0.001). 
CBNK cells also had a significantly higher CD57 expression over CBCD34+-NK 
cells (p < 0.001) showing that CBCD34+-NK cells have a less differentiated 
phenotype over PBNK cells and CBNK cells. 
 
Figure 3.5. How the percentage expression of CD57 by CBCD34+ NK cells 
compares to PBNK cells and CBNK cells. A) Representative FACS plot CD57 
expression B) Percentage CD57 expression (± range) of CBCD34+-NK cells (n = 9), 
PBNK cells (n = 9) and CBNK cells (n = 9) is shown. *** p < 0.001. 
 
3.2.4. K562 cells can be killed in vivo by NK cells differentiated in vitro 
 
The development of a successful cellular immunotherapy is dependent on the NK 
cells differentiated in vitro being able to function and have a cytotoxic effect in vivo. 
Due to the absence of MHC class I on K562 cells, they are highly susceptible to NK 
cell-mediated lysis and are therefore considered the gold standard target for assessing 
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NK cell cytotoxic function (Pross et al., 1981). Further it has previously been shown 
that resting CBCD34+-NK cells are able to kill K562 cells in vitro (Luevano et al., 
2014). It was therefore investigated whether the differentiated NK cells could kill the 
NK cell susceptible K562 cell line in an NSG mouse model. Irradiated NSG mice 
were injected with 1 x 106 GFP-K562 cells and then injected 24 h later with either 20 
x 106 CBCD34+-NK cells or PBS as a control. After 24 h, the bone marrow, lungs, 
liver and spleen were harvested and analysed by flow cytometry. 
 
A representative FACS plot analysis of a subject injected with K562 cells only and 
K562 cells plus NK cells can be seen in figure 3.6 A and B respectively. GFP-K562 
cells could be detected in the bone marrow, 6.24 % (4.3 – 6.99) liver, 10.46 % (9.69 
– 11.4) lungs, 1.07 % (0.45 – 7.42) and spleen, 65.8 % (57.1 – 70.2) 48 h post 
injection (figure 3.7A). There was a significantly decreased percentage of GFP-K562 
cells detected in the liver, 5.6 % (4.47 – 9.64) and spleen, 52.4 % (37.4 – 59.7) of the 
NSG mice injected with CBCD34+-NK cells in comparison to the control (p < 0.05). 
To support this CBCD34+-NK cells were shown to persist in these organs where 23.8 
% (17.9 – 33.9) was detected in the liver and 6.24 % (3.31 – 17.3) was detected in 
the spleen (figure 3.7B) demonstrating killing of GFP-K562 cells. Resting 
CBCD34+-NK cells are therefore fully functional in vivo. 
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Figure 3.6. Representative FACS Plot of Killing of K562 cells in vivo. A) Spleen 
of control mouse injected with GFP-K562 cells only. B) Spleen of mouse injected 
with GFP-K562 cells and CBCD34+-NK cells. 
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Figure 3.7. Killing of K562 cells in vivo. NSG mice were injected with GFP-K562 
cells followed by CBCD34+-NK cells (n=5) or PBS (n=4) A) Median percentage of 
GFP-K562 ( range) detected in the BM, liver, lungs and spleen. B) Median 
percentage of NK cells ( range) detected in the bone marrow, liver, lungs and 
spleen. Statistical analysis was performed using Mann-Whitney test * p<0.05. 
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3.2.5. Resting CBCD34+ and PBNK cells are able to target K562 cells in vitro 
but not patient AML blasts 
 
Previously it has been shown that CBCD34+-NK cells are able to target the NK 
susceptible cell line K562 in vitro and in vivo. It is fundamental to therefore identify 
how the cytotoxicity of CBCD34+-NK cells compares to freshly isolated PBNK cells 
and identify if they are capable of demonstrating a cytotoxic effect against tumour 
cells in vitro. This being a key function required for targeting malignancies and 
preventing relapse in patients. Cytotoxicity was assessed by a flow cytometry based 
method as primary cells are poor at up taking Cr51. Figure 3.7A shows that resting 
CBCD34+-NK cells and PBNK cells were capable of targeting the NK cell 
susceptible cell line K562 to the same degree, 38.04 % (14.94 – 49.69) vs 46.40 % 
(41.92 – 50.89) respectively showing that NK cells from both cell sources are fully 
functional in vitro supporting previous literature (Luevano et al., 2014). NK cells of 
any source must also be able to kill patient samples in order to produce a translatable 
clinical therapy. Cytotoxicity was therefore assessed against AML samples varying 
in severity from M1-M4. It can be seen in figure 3.7B that there was some degree of 
killing observed by both CBCD34+-NK cells 2.66 % (0 – 15.37) and PBNK cells 
(3.32 % (0 – 20.39) however these results were variable and inconsistent. There was 
no significance difference observed between NK cells from either source, further 
activation of NK cells is therefore required. 
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Figure 3.8. Killing of AML and K562 cells in vitro by CBCD34+-NK cells and 
PBNK cells. A flow cytometry based assay was used to assess in vitro cytotoxicity 
A) Median specific K562 lysis ( range) by CBCD34+-NK cells (n = 8) and PBNK 
cells (n = 8), 8 different donors were used. B) Median specific AML lysis ( range) 
by CBCD34+-NK cells (n = 18) and PBNK cells (n = 18) in vitro against 6 different 
AML samples, 18 different donors were used. 
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3.3. Discussion 
 
The differentiation of NK cells from CBCD34+-cells offer a rich source of highly 
functional cells that could provide an off-the-shelf immunotherapy. Here the function 
of the CBCD34+-NK cells is further characterised in order to elucidate how their 
function compares to resting PBNK cells and CBNK cells. 
 
NK cell proliferation post infusion is essential for the development of a successful 
immunotherapy. However long-term culture of lymphocytes prior to clinical 
application has been associated with poor proliferation in vivo (Childs and Berg, 
2013). Previous literature documents the in vivo proliferation of NK cells expanded 
from PBNK cells and CBNK cells (Alici et al., 2008, Fujisaki et al., 2009b, Berg et 
al., 2009, Shah et al., 2013). To our knowledge this is the first study that has 
observed successful proliferation in vitro of NK cells differentiated in vitro from CB 
CD34+ cells. It is further shown here that CBCD34+-NK cells can proliferate to the 
same degree as resting PBNK cells and CBNK cells following additional cytokine 
stimulation in vitro. This will therefore enable expansion of the CBCD34+-NK cells 
once infused into a patient and successful targeting of malignancies.  
 
It has been identified that as normal haematopoetic cells divide in vitro or in vivo 
telomere length is reduced, telomere length is therefore considered a “molecular 
clock that triggers senescence” (Bodnar et al., 1998). This is the first time that the 
telomere length of CBCD34+-NK cells has been compared to that of PBNK cells and 
CBNK cells. Expansion of PBNK cells using the K562 cell line genetically modified 
to express 4-1BB ligand and interleukin 15 (K562-mb15-41BBL) has been shown to 
achieve an expansion of 277-fold in 21 days, however further proliferation was 
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limited by telomere shortening and cell senescence. Telomere shortening could be 
reversed by implementation of the human telomerase reverse transcriptase gene, 
demonstrating a fundamental relationship between telomere length and NK cell 
survival (Fujisaki et al., 2009a). Telomere length of NK cells differentiated from 
iPSCs was much longer than those expanded from PB (Scaria et al., 2014). Further 
Ouyang (Ouyang et al., 2007) showed that reduced telomere length could be 
attributed to poor NK cell function in the elderly. Interestingly it can be seen here 
that CBCD34+-NK cells have telomeres longer than PBNK cells and CBNK cells 
implying their road to cell senescence is longer and are therefore likely to have an 
improved persistence in vivo and be able to target tumour cells more efficiently. 
 
CD57 has been identified as an NK cell marker of terminal differentiation and poor 
responsiveness to cytokines (Lopez-Verges et al., 2010). Characterising the 
expression of CD57 on NK cells could therefore aid in understanding how cells 
might respond in vivo. Other work has suggested that the expression of CD57 is a 
marker of NK cell maturation and enhanced cytotoxic capacity instead of an 
indicator of cell anergy (Nielsen et al., 2013). However it can be seen here that 
CBCD34+-NK cells have a significantly lower expression of CD57 in comparison to 
PBNK cells and CBNK cells without any variation in cytotoxic effect against the 
K562 cell line or AML patient blasts in comparison to PBNK cells. It can therefore 
be hypothesized that a CD57 expression threshold is to be reached to demonstrate 
full NK cell maturation but as expression increases past this threshold cell 
senescence can be correlated. Further as an increased expression of CD57 has also 
been associated with a reduced sensitivity to cytokines this could further support 
previous work that CBCD34+-NK cells can survive and persist for longer in vivo 
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over other NK cell sources (Luevano et al., 2014). Interestingly it can also be 
observed here that resting CBCD34+-NK cells have a much higher persistence in 
vivo in comparison to another method of differentiating NK cells in vitro from CB 
CD34+ cells (Cany et al., 2013) where cells 2.7-2.8 % of cells were detected in the 
lungs in comparison to 9.93 %-27.4% here and 2.4 % - 2.6 % was detected in the 
liver in comparison to 17.9 % - 33.9 % here.  
 
Down-regulation of EOMES and TBET has been identified as being associated with 
an exhausted cell phenotype resulting in an impaired function and inability to target 
tumour cells in both mice (Gill et al., 2012) and humans (Simonetta et al., 2015). It is 
shown here that the molecular levels of EOMES and TBET expressed by CBCD34+-
NK cells is equivalent to those expressed by freshly isolated PBNK cells and CBNK 
cells. Further, resting CBCD34+-NK cells are capable of killing K562 cells in vitro at 
a comparable level to resting PBNK cells (figure 3.7) and other methods of 
differentiating NK cells in vitro from CB CD34+ cells (Spanholtz et al., 2010, 
Spanholtz et al., 2011). CBCD34+-NK cells therefore do not express an exhausted 
phenotype or have the accompanying poor cytotoxicity. 
 
It can therefore be concluded that CBCD34+-NK cells demonstrate a younger cell 
profile without loss of function. This implies an enhanced ability to survive and 
proliferate when used as a cell therapy in the clinic demonstrating an advantage over 
PBNK cell and CBNK cells.   
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Chapter 4 
 
The Activation of NK Cells 
Differentiated in vitro from 
CBCD34+ Cells 
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4.1. Introduction 
 
The ability of CBCD34+-NK cells to target patient cancer cells in vitro is essential in 
order to produce a clinically viable immunotherapy. It has been shown that resting 
CBCD34+-NK cells and PBNK cells exhibit low cytotoxicity against AML blasts in 
vitro (chapter 3), an additional activation step is therefore required. The activation of 
NK cells with cytokines such as IL-2 is known to enhance the effector function of 
NK cells and is commonly used for NK cell activation prior to infusion and for in 
vivo expansion in many NK cell clinical trials (Miller et al., 2005, Bachanova et al., 
2014, Escudier et al., 1994, Krause et al., 2004, Ishikawa et al., 2004, Lundqvist et 
al., 2011, Burns et al., 2003, Parkhurst et al., 2011, Szmania et al., 2014, Geller et al., 
2011, Shi et al., 2008a). In vivo IL-2 infusion refers to the administration of IL-2 
intravenously at various time intervals after the initial cell therapy to assist with the 
survival and proliferation of the cells. Unfortunately, in vivo administration of IL-2 
has shown toxic effects such as vascular leak syndrome (Krieg et al., 2010) and the 
preferential expansion of regulatory T cells that suppress NK cell function 
(Ahmadzadeh and Rosenberg, 2006, Miller et al., 2005, Bachanova et al., 2014).  
 
Many clinical studies have focused mainly on the use of IL-2 to activate NK cells as 
until recently it was the only cytokines that were approved for clinical use. It has 
however been reported that cytotoxic function can also be enhanced by the use of 
other cytokines such as IL-12 (Gaddy et al., 1995), IL-15 (Gaddy and Broxmeyer, 
1997) and IL-18 (Nomura et al., 2001). Further it has also been shown that PBNK 
cells and CBNK cells show differential activation profiles in response to different 
cytokines where CBNK cells may have a reduced response to IL-2 in comparison to 
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PBNK cells. The combination of IL-15 and IL-18 can significantly enhance the 
proliferation and cytokine production of CBNK cells (Alnabhan et al., 2014). 
 
Previously it has been shown that tumour-mediated priming of NK cells has an 
equivalent cytotoxicity against resistant NK cell lines as cytokine activation (North 
2007). NK cell priming is a novel method of stimulating NK cells based on a two-
step activation process, referred to as priming and triggering. A lysate developed 
from an acute lymphoblastic leukaemia cell line known as CTV-1 has been shown to 
prime resting PBNK cells without triggering any cytokine release or cytotoxic 
activity enabling significantly up regulated cytotoxicity against numerous targets that 
were previously resistant to NK cell lysis (North 2007, Sabry 2011). This activation 
methodology has been approved for clinical application and is currently being 
utilized in ongoing clinical trials where so far persistence and GvL has been 
observed with limited toxicity (Fehniger et al., 2014, Kottaridis et al., 2015).This 
method of activation was therefore adopted to identify if it enhanced CBCD34+-NK 
cell function and how this compared to the cytotoxicity induced by primed PBNK 
cells and CBNK cells. As IL-2 is currently used routinely in numerous clinical trials 
to activate NK cells, a comparison is necessary with priming to confirm which is the 
superior activation process for NK cell function against resistant cell lines. Further it 
is important to assess how the cytotoxicity of the primed cells compares to PBNK 
cells and CBNK cells.  
 
In this chapter it is assessed how tumour-mediated priming compares to cytokine 
activation of NK cells at targeting tumour cells in vitro and in vivo. The comparative 
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response of CBCD34+-NK cells to PBNK cells and CBNK cells will aid the 
establishment of the most superior NK cell source for clinical application. 
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4.2. Results 
 
4.2.1. Resting NK cells can be primed by CTV-1 lysate to kill K562 cells and 
patient AML blasts in vitro 
 
As observed in chapter 3 CBCD34+-NK cells and PBNK cells exhibit poor 
cytotoxicity against patient AML blasts. Without robust killing of patient AML cells 
in vitro it is impossible to take an NK cell immunotherapy to the clinic. Therefore 
activation of NK cells differentiated in vitro prior to infusion would be necessary. 
Clinical trials have shown NK cell immunotherapy to be non-toxic and some efficacy 
has been observed. Cytokine activation is still yet to produce a clinically robust cell 
product (Cheng et al., 2013) an alternative method of activation was therefore 
considered. NK cell priming has been shown to significantly up-regulate NK cell 
cytotoxicity against NK cell resistant targets, primed CBCD34+NK cells could 
therefore potentially produce a more robust and clinically effective therapy.  
 
The ability of NK cells to target the K562 cell line is the gold standard for assessing 
cytotoxic activity; therefore first it was assessed if resting and primed CBCD34+-NK 
cells could kill K562 cells as a control. Resting CBCD34+-NK cells could kill the 
K562 cell line, 16.99 % (9.16 – 63.97) showing the cells are fully functional however 
the primed NK cells showed a significantly enhanced cytotoxic ability, 77.97 % 
(56.87 – 85.58) (p < 0.001) (Figure 4.1A) supporting previous work (North et al., 
2007, Sabry et al., 2011) and demonstrating how priming enhances NK cell killing. 
Further, figure 4.1B shows that primed, in opposition to resting, CBCD34+-NK cells 
are able to consistently target patient AML blasts in vitro. Where resting CBCD34+-
NK cells are able to specifically lyse 9.01 % (0 – 16.49) of patient AML blasts over 
43.51 % (32.90 – 70.64) by primed CBCD34+-NK cells (p < 0.0001). 
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Figure 4.1. Resting NK cells can be primed by CTV-1 lysate to kill K562 cells 
and patient AML blasts in vitro. A flow cytometry based assay was used to analyse 
in vitro killing A) Median specific K562 lysis ( range) by resting CBCD34+-NK 
cells (n = 10) and primed CBCD34+-NK cells (n = 10) is shown, 10 different donors 
were used. B) Median specific AML lysis ( range) by resting CBCD34+-NK cells (n 
= 27 donors) and primed CBCD34+-NK cells (n = 27 donors) is shown against 9 
AML samples. Statistical analysis was performed using Mann-Whitney test. **** p < 
0.0001. 
 
4.2.2. Comparing the lysis of patient AML blasts, K562 cells and RAJI cells by 
resting, primed and IL-2 stimulated CBCD34+-NK cells, PBNK cells and 
CBNK cells 
 
As priming has been shown to be effective at activating CBCD34+-NK cells to target 
patient AML blasts in vitro a comparison with IL-2 activation would identify which 
is the superior activation process for NK cell function against resistant cell lines. 
Killing activity was assessed by flow cytometry to identify specific cell lysis by 
resting, primed and IL-2 stimulated CBCD34+-NK cells, PBNK cells and CBNK 
cells against patient AML blasts, the NK cell susceptible cell line K562 and the NK 
cell resistant cell line RAJI. As RAJI is well documented as being resistant to NK 
cell lysis (Hasenkamp et al., 2006) its inclusion here acts as a control to demonstrate 
that the cells have been successfully activated to overcome resistant cell types. 
Figure 4.2A shows the specific lysis of patient AML blasts by CBCD34+-NK cells 
where primed NK cells are significantly more cytotoxic than resting or IL-2 
stimulated NK cells, 55.03 % (41.63 – 61.91) vs 5.90 % (0 – 13.12) and 6.32 % (0 – 
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21.33) respectively. Even though K562 cells are susceptible to NK cell lysis the 
same significant trend is observed where priming results in specific lysis of 76.80 % 
(58.83 – 84.50) against resting CBCD34+-NK cells 51.02 % (10.31 – 63.97) and IL-2 
stimulated CBCD34+-NK cells 44.40 % (23.80 – 54.73). Assessment of CBCD34+-
NK cell lysis against the RAJI cell line further confirms the ability of priming to 
activate NK cells to target resistant cells. Here primed CBCD34+-NK cells are 
capable of targeting 43.42 % (34.95 – 85.51) of the RAJI resistant cell line in 
comparison to 7.67 % (3.03 – 8.29) by resting CBCD34+-NK cells and 7.69 % (3.04 
– 50.69) by IL-2 stimulated CBCD34+-NK cells. The same trend of significantly up-
regulated cell lysis is also observed by primed PBNK cells and primed CBNK cells 
against patient AML blasts (p< 0.001), K562 cells (p < 0.01) and RAJI cells (p < 
0.01) (Figure 4.2B-C). 
 
 
 
 117 
 
Figure 4.2. Comparing the lysis of patient AML blasts, K562 cells and RAJI 
cells by resting, primed and IL-2 stimulated CBCD34+-NK cells, PBNK cells 
and CBNK cells. A flow cytometry based assay was used to analyse in vitro killing. 
A) Median specific lysis ( range) of AML (n = 15) against 5 different AML 
samples, K562 cells (n = 5) and RAJI cells (n = 5) by resting, primed and IL-2 
stimulated CBCD34+-NK cells. B) Median specific lysis ( range) of AML (n = 15) 
against 5 different AML samples, K562 cells (n = 5) and RAJI cells (n = 5) by 
resting, primed and IL-2 stimulated PBNK cells. C) Median specific lysis ( range) 
of AML (n = 15) against 5 different AML samples, K562 cells (n = 5) and RAJI cells 
(n = 5) by resting, primed and IL-2 stimulated CBNK cells. Statistical analysis was 
performed using Mann-Whitney test * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Figure 4.3 compares the level of specific lysis by primed CBCD34+-NK cells, 
primed PBNK cells and primed CBNK cells against patient AML blasts. It can be 
seen that primed CBCD34+-NK cells were significantly less cytotoxic than primed 
PBNK cells, 54.17 % (41.63 – 61.91) vs 56.57 % (22.05 – 73.84) (p < 0.05) and 
primed CBNK cells, 61.34 % (45.43 – 74.50) (p < 0.01). This difference however is 
only 2.394 % less than PBNK cells and 7.164 % less than CBNK cells and is 
unlikely to have any improved clinical implications. Taken together, it can therefore 
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be concluded that priming NK cells overnight is a significantly better method of 
activation over IL-2 stimulation. 
 
Figure 4.3. The cytotoxicity of primed CBCD34+ NK cells, primed PBNK cells 
and primed CBNK cells against patient AML blast samples in vitro. A flow 
cytometry based assay was used to assess in vitro killing. The median specific lysis 
( range) by CBCD34+ (n = 15), PBNK (n = 15) and CBNK cells (n = 15) is shown 
against 5 AML samples, 15 different donors were used. Statistical analysis was 
performed using Mann-Whitney test * p < 0.05. 
 
4.2.3. Are resting or primed CBCD34+-NK cells capable of killing patient AML 
blasts in vivo 
 
After establishing that priming led to higher levels of cytotoxicity in vitro against 
patient AML blasts by CBCD34+-NK cells it was then necessary to analyse if this 
function was maintained in vivo. To identify this irradiated NSG mice were injected 
with 1 x 106 PKH26 labelled AML blasts, and then injected 24 h later with either 20 
x 106 resting CBCD34+-NK cells or 20 x 106 primed CBCD34+-NK cells or PBS as a 
control. After 24 h, the bone marrow, lungs, liver and spleen were harvested and 
analysed by flow cytometry.  
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PKH26 labelled AML blasts could be detected in the BM 33.0 % (1.51 – 52.0), liver 
22.7 % (1.08 – 80.0), lungs 25.0 % (0.85 – 60.0) and spleen 6.75 % (0.10 – 14.6) 48 
h post infusion (figure 4.4A). Killing of patient AML blasts was observed in the liver 
2.92 % (0.51 – 23.9), spleen 1.63 % (0.23 – 5.84) and lungs 3.49 (0.38 – 16.1) of the 
mice injected with resting CBCD34+-NK cells. Interestingly, there was no significant 
difference observed in the level of killing in the liver 3.29 % (0.6 – 19.1), spleen 0.2 
% (0 – 4.9) or lungs 2.65 % (1.14 – 5.88) by the mice injected with primed 
CBCD34+-NK cells in comparison to those injected with resting CBCD34+-NK cells. 
There was no reduction in the percentage of PKH26 labelled AML cells in the bone 
marrow whether CBCD34+-NK cells were primed or not. Resting and primed 
CBCD34+-NK cells could be detected in all organs analysed with no significant 
difference observed in persistence. Where in the BM 13.40 % (1.60 – 43.50) vs 
27.50 % (9.83 – 51.0) of resting and primed CBCD34+-NK cells were seen 
respectively. Similarly in the liver 48.10 % (8.45 – 72.80) resting CBCD34+-NK 
cells vs 68.90 % (6.38 – 76.10) primed CBCD34+-NK cells was detected, in the 
spleen 9.20 % (2.35 – 62.50) resting CBCD34+-NK cells vs 9.17 % (2.80 – 52.0) 
primed CBCD34+-NK cells was seen and in the lungs 63.6 % (16.1 – 82.10) resting 
CBCD34+-NK cells vs 66.1 % (32.7 – 83.3) primed CBCD34+-NK cells was 
identified (figure 4.4B). Therefore, it can be concluded that CBCD34+-NK cells 
might not require prior activation to have a cytotoxic impact on patient AML blasts 
in vivo. 
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Figure 4.4. The cytotoxicity of resting or primed CBCD34+-NK cells against 
patient AML blasts in vivo A) Median percentage of PKH26 labelled AML cells ( 
range) detected in the BM, liver, lungs and spleen (n = 6) is shown. B) Median 
percentage of NK cells ( range) detected in the bone marrow, liver, lungs and 
spleen (n = 6) is shown. Statistical analysis was performed using Mann-Whitney test 
** p < 0.01. 
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4.2.4. Comparing the proliferation of cytokine stimulated and primed 
CBCD34+-NK cells  
 
In order to identify why CBCD34+-NK cells do not require prior activation to 
observe a cytotoxic effect in vivo we compared the difference in proliferation 
following cytokine stimulation and priming. The comparison of IL-2 and IL-15 
stimulation with priming was performed as it has been well documented that these 
cytokines are associated with enhanced proliferation, cytotoxicity and survival of NK 
cells (Trinchieri et al., 1984, Carson et al., 1997).  
 
As can be seen in figure 4.5 the percentage expression of IL-2 and IL-15 receptors 
was equivalent on resting or primed CBCD34+-NK cells and PBNK cells. Where 
resting and primed CBCD34+-NK cells had an expression of 16.0 % (10.0 – 23.9) 
and 17.35 % (7.87 – 25.9) respectively of IL-15R in comparison to 16.55 % (11.8 – 
35.4) on resting PBNK cells and 17.35 % (13.2 – 17.3) on primed PBNK cells. 
Resting CBCD34+-NK cells had an expression of 37.2 % (27.7 – 56.1) of IL-2R 
and primed CBCD34+-NK cells had an expression of 35.95 % (21.4 – 41.41) in 
comparison to 25.30 % (12.0 – 42.8) and 25.45 % (18.2 – 30.4) on resting and 
primed PBNK cells respectively. The expression of IL-2R on resting and primed 
CBCD34+-NK cells was 85.35 % (63.8 – 87.2) and 80.55 % (68.3 – 88.2) and on 
resting and primed PBNK cells it was 57.85 % (41.3 – 71.9) and 61.45 5 (44.10 – 
81.2). CBNK cells were omitted from this analysis as there are no existing 
comparative studies using primed CBNK cells.  
 
CFSE analysis was used to compare the proliferation of CBCD34+-NK cells and 
PBNK cells after activation with IL-2, IL-15 or tumour-mediated priming. Figure 4.6 
shows that CBCD34+-NK cells proliferated significantly more when activated with 
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cytokines over priming where at day 35 of culture (day 7 post stimulation) the MFI 
of CFSE after priming was 13374.5 (12186 – 14749) in comparison to IL-2 
stimulation 9446 (7506 – 10732) and IL-15 stimulation 9638 (7826 – 12232) (p < 
0.01). This difference was not observed with PBNK cells, which could account for 
why it may not be necessary to prime CBCD34+-NK cells to achieve cytotoxicity in 
vivo. This could be because upon infusion into an irradiated mouse the cytokine 
storm could potentially activate the NK cells to proliferate significantly more than 
primed NK cells leading to better killing of tumour cells. 
 
 
 
 
 
 
 123 
 
 
Figure 4.5. Percentage expression of IL-2 and IL-15 receptors by resting and 
primed CBCD34+-NK cells and PBNK cells. A) Representative FACS plots of 
receptor expression B) Median percentage expression  range is shown after 
electronic gating on the viable lymphocyte population and CD56+CD3- (n = 6). 
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Figure 4.6. Comparing the proliferation of cytokine stimulated and primed 
CBCD34+-NK cells. CFSE analysis was used to assess proliferation in vitro after 
stimulation with 200 IU IL-2, 20 ng/mL IL-15 or priming with CTV-1 lysate. A) The 
median MFI of CFSE ( range) at D30, 33 and 35 of NK cell culture corresponding 
to D2, D5 and D7 post activation of CBCD34+-NK cells (n = 4) is shown. B) The 
median MFI of CFSE ( range) at D2, 5 and 7 post activation of PBNK cells (n = 4) 
is shown. Statistical analysis was performed using Mann-Whitney test * p < 0.05. 
 
4.2.5. The comparison of resting, primed and IL-2 stimulated CBCD34+-NK 
cells against PBNK cells and CBNK cells at killing solid tumour cell lines 
 
It has been well documented that solid tumours are notoriously difficult to target by 
immunotherapy (Melero et al., 2014). Therefore after successfully showing that 
primed CBCD34+-NK cells can target AML it is interesting to identify if they have a 
cytotoxic effect against solid tumour cell lines. It was assessed if resting, primed or 
IL-2 stimulated CBCD34+-NK cells as well as PBNK cell and CBNK cell controls 
could target solid tumour cell lines in vitro. Specific Lysis of the colon cancer HT29 
(figure 4.7A), breast adenocarcinoma MCF7 (Figure 4.7B) and renal cell carcinoma 
A478 (figure 4.7C) was assessed by the flow cytometry based cytotoxicity assay. 
These data show that primed NK cells of any source were highly superior at targeting 
tumour cells over resting and IL-2 stimulated NK cells (p < 0.01). Further it is 
interesting to note that resting and IL-2 stimulated CBCD34+-NK cells were 
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significantly more cytotoxic than PBNK cells and CBNK cells (p < 0.05) when 
targeting the colon cancer cell line HT29 (Figure 4.7A). 
 
Figure 4.7. The cytotoxicity of resting, primed and IL-2 stimulated CBCD34+-
NK cells, PBNK cells and CBNK cells against solid tumour cell lines. A flow 
cytometry based assay was used to assess in vitro killing. A) Median specific lysis ( 
range) of HT-29 by resting, primed and IL-2 stimulated CBCD34+(n = 6), PBNK (n 
= 6) and CBNK cells (n = 6) is shown. B) Median specific lysis ( range) of MCF-7 
by resting, primed and IL-2 stimulated CBCD34+ (n = 6), PBNK (n = 6) and CBNK 
cells (n = 6) is shown. C) Median specific lysis ( range) of A478 by resting, primed 
and IL-2 stimulated CBCD34+ (n = 6), PBNK (n = 6) and CBNK cells (n = 6) is 
shown. Statistical analysis was performed using Mann-Whitney test * p < 0.05 ** p 
< 0.01.  
 
Development of drug resistance to targeted therapies in cancer patients has initialised 
the interest in combining drug-based therapy with immunotherapy (Sottile et al., 
2016). Therefore it is of interest to identify if resting, primed or IL-2 stimulated 
CBCD34+-NK cells could also target solid tumour cell lines that have developed 
selective resistance to current clinical therapies. Here the use of melanoma cells lines 
that were susceptible and resistant to inhibitors targeting activating mutants of the B-
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Raf kinase (BRAF inhibitors) were studied. Specific lysis was evaluated by a flow 
cytometry based cytotoxicity assay against cell lines that had been produced from 
both primary (MELHO) and metastatic (1520) melanoma that were both susceptible 
and resistant to BRAF inhibitors. It can be seen in figure 4.8 that priming is 
significantly superior at targeting both primary and metastatic melanoma cell lines 
irrelevant of the NK cell source. This trend is not observed by either resting or IL-2 
stimulated NK cells. These data therefore support what has been observed previously 
that priming NK cells with tumour cells is the more desirable form of NK cell 
activation over cytokine stimulation for clinical application. 
Figure 4.8. The cytotoxicity of resting, primed and IL-2 stimulated CBCD34+-
NK cells, PBNK cells and CBNK cells against melanoma cell lines resistant and 
susceptible to BRAF inhibitors. A flow cytometry based assay was used to assess 
in vitro killing. A) Median specific lysis ( range) of susceptible MELHO by resting, 
primed and IL-2 stimulated CBCD34+(n = 6), PBNK (n = 6) and CBNK cells (n = 6) 
is shown. B) Median specific lysis ( range) of resistant MELHO by resting, primed 
and IL-2 stimulated CBCD34+ (n = 6), PBNK (n = 6) and CBNK cells (n = 6) is 
shown. C) Median specific lysis ( range) of resistant 1520 by resting, primed and 
IL-2 stimulated CBCD34+(n = 6), PBNK (n = 6) and CBNK cells (n = 6) is shown. 
Statistical analysis was performed using Mann-Whitney test * p < 0.05 ** p < 0.01. 
D) Median specific lysis ( range) of susceptible 1520 by resting, primed and IL-2 
stimulated CBCD34+ (n = 6), PBNK (n = 6) and CBNK cells (n = 6) is shown. 
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4.2.6. Comparing the pathway involved in killing by primed CBCD34+, PBNK 
cells and CBNK cells 
 
To further assess which killing mechanism might be involved in targeting NK 
resistant cells by primed NK cells a blocking experiment was carried out. Blocking 
of TRAIL, FasL, NKG2D and CD16 was analysed. TRAIL and FasL are death 
receptors that can directly eliminate targets post engagement without synergy with 
any other activating receptors (Lavrik et al., 2005), NKG2D is a co-engagement 
activating receptor and CD16, the mediator of ADCC (Moretta et al., 2000). NK 
cells were primed post blocking and an in vitro flow cytometry cytotoxicity assay 
was carried out against the NK cell resistant cell line RAJI. A resistant cell line was 
used in this analysis as if no killing of RAJI cells is observed after priming and 
blocking of this specific marker it can be concluded that this maybe the killing 
mechanism involved. The level of specific lysis of the RAJI cell line by resting, 
primed, blocked and isotype controls of CBCD34+-NK cells, PBNK cells and CBNK 
cells was evaluated.  
 
As can be seen in figure 4.9 the percentage expression of these receptors on resting 
or primed CBCD34+-NK cells, PBNK cells and CBNK cells was unchanged. After 
blocking TRAIL (Figure 4.10A), FasL (Figure 4.10B) and NKG2D (figure 4.10C) 
there was no difference observed in the specific lysis of RAJI cells in comparison to 
the unblocked controls or relevant isotype controls. This indicates that primed 
CBCD34+-NK cells, PBNK cells or CBNK cells do not involve these receptors in the 
killing of NK cell resistant target cells. Blocking of CD16 (figure 4.10D) however 
showed significantly reduced cytotoxicity against RAJI cells when compared to the 
isotype control of any NK cell source, CBCD34+ 30.82 % (23.38 – 45.48) vs 41.51 
% (34.71 – 57.42) (p < 0.001), PBNK 37.35 % (20.94 – 56.68) vs 49.85 (37.34 – 
 128 
72.58) (p < 0.01) and CBNK cells 23.39 % (20.22 – 43.35) vs 42.45 % (31.25 – 
70.62)) (p < 0.001). It can therefore be concluded that CD16 is a key pathway 
involved for killing NK cell resistant targets by primed NK cells.  
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Figure 4.9. A) Representative FACS plots of receptor expression  B) Percentage 
expression of receptors involved in NK killing by resting and primed CBCD34+-
NK cells, PBNK cells and CBNK cells. Median percentage expression  range is 
shown after electronic gating on the viable lymphocyte population and CD56+CD3- 
(n = 6). 
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Figure 4.10. Comparing the pathway involved in killing by primed CBCD34+, 
PBNK and CBNK cells. NK cells were blocked prior to priming before analysing 
receptor involvement by an in vitro flow cytometry based assay against the NK 
resistant cell line RAJI. A) Median specific lysis ( range) by resting, primed 
isotype, primed and primed TRAIL blocked CBCD34+ (n = 6), PBNK (n = 6) and 
CBNK cells (n = 6) is shown. B) Median specific lysis ( range) by resting, primed 
isotype, primed and primed FasL blocked CBCD34+ (n = 6), PBNK (n = 6) and 
CBNK cells (n = 6) is shown. C) Median specific lysis ( range) by resting, primed 
isotype, primed and primed NKG2D blocked CBCD34+ (n = 6), PBNK (n = 6) and 
CBNK cells (n = 6) is shown. D) Median specific lysis ( range) by resting, primed 
isotype, primed and primed CD16 blocked CBCD34+ (n = 6), PBNK (n = 6) and 
CBNK cells (n = 6) is shown. 
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4.3. Discussion 
 
Translational success of NK cell immunotherapy is dependent on being able to 
produce a cell product with an optimum activation status that will target 
malignancies in a robust manner. Here the use of IL-2 mediated NK cell activation 
and tumour-mediated NK cell priming is compared to identify which would produce 
the most cytotoxic cell product. The cytotoxicity of the resting, primed and IL-2 
stimulated CBCD34+-NK cells is equivalent to both PBNK cells and CBNK cell 
controls when targeting K562 cells, patient AML blasts, RAJI cells and solid tumour 
cell lines. This demonstrates that this key NK cell function necessary to target patient 
tumours is uncompromised whether NK cells are differentiated in vitro from 
CBCD34+ cells or in vivo as can be concluded by analysing the function of freshly 
isolated adult PBNK cells and CBNK cells. Interestingly, resting CBCD34+-NK cells 
were significantly better at targeting the HT-29 colon adenocarcinoma cell line and 
the MELHO melanoma cell line resistant to BRAF inhibitors over resting PBNK 
cells and CBNK cells. This could indicate that resting CBCD34+-NK cells are less 
susceptible to the immunosuppressive features of these cell types.  
 
Cytokine-mediated activation of NK cells of any source did not result in equivalent 
cytotoxicity as tumour-mediated priming as previously seen (North et al., 2007). This 
is likely a result of stimulation time, where here NK cells were cytokine activated 
overnight to mimic the same protocol used to prime NK cells with tumour lysate, 
other studies have routinely stimulated NK cells with IL-2 for 2-5 days (Yu et al., 
2000). Here an increased effector to target ratio of 40 : 1 was also used and 
cytotoxicity against K562 cells was 75 % and 50 % against RAJI cells as assessed by 
Cr51 release assay (Yu et al., 2000). In comparison as shown in this chapter primed 
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PBNK cells have a cytotoxicity of around 80 % against K562 cells and 60 % against 
RAJI cells after a significantly reduced incubation time. Tumour-mediated priming is 
therefore a superior activation method as an overnight stimulation is much more 
economically efficient than a 2-5 day stimulation for clinical application and there is 
no compromise on cytotoxic efficacy. 
 
It was observed that priming was not necessary to detect killing in vivo of patient 
AML blasts. This could be the result of significantly reduced proliferation by primed 
CBCD34+-NK cells in comparison to cytokine stimulation that was not observed in 
PBNK cells. Even though there is no difference observed in the IL-2 and IL-15 
receptor expression by CBCD34+-NK cells and PBNK cells increased expression of 
CD57 has also been associated with a reduced sensitivity to cytokines (Lopez-Verges 
et al., 2010) which is observed following priming and on the surface of PBNK cells 
in comparison to CBCD34+-NK cells.  
 
Blocking of cytotoxicity pathways shows that killing by primed CBCD34+ NK cells 
and CBNK cells utilises the same biological pathway as PBNK cells supporting 
previous literature (Sabry et al., 2011). However the shedding of the CD16 receptor 
that has previously been associated with NK cell priming was not observed. Previous 
work has shown that Adam 17 inhibition prevents CD16 shedding enhances NK cell 
cytotoxicity (Romee et al., 2013) which could be the case here. 
 
In conclusion tumour-mediated priming is far superior at targeting cells resistant to 
NK cell lysis over cytokine-mediated activation irrelevant of the NK cell source. 
Further CBCD34+-NK cells, PBNK cells and CBNK cells utilise the same CD16 
pathway to enhance their function. CBCD34+-NK cells do not require prior 
 133 
activation to achieve cytotoxicity against patient AML blasts in vivo and higher 
numbers of NK cells can be differentiated from CB CD34+ cells numbers than 
isolated from PB. This makes CBCD34+-NK cells a more favorable cell product as a 
higher dose of resting cells could be infused in comparison making way for a more 
economically viable cellular immunotherapy. 
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 Chapter 5: Cryopreservation of Natural Killer cells differentiated in vitro from 
umbilical cord blood CD34+ cells 
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5.1. Introduction 
 
NK cells are lymphocytes of the innate immune system capable of targeting 
cancerous and virally transformed cells without prior sensitisation. There has 
therefore been a lot of interest in taking advantage of this cytotoxic effect to target 
transformed and malignant cells via immunotherapy. NK cell immunotherapy has 
been shown to be safe and feasible as an NK cell therapy alone and in combination 
with HSCT. In humans their ability to generate an immune response against 
leukaemic cells and prevent graft rejection (Ruggeri et al., 2002) without causing 
GvHD (Miller et al., 2005) have increased interest in utilising NK cells as a 
supportive therapy for HSCT by preventing relapse without the risk of causing toxic 
side effects.  
 
Obtaining cells for therapy is a challenge as only low numbers of NK cells are 
present in PB and high cell numbers are necessary to induce an effective cytotoxic 
function. The exact NK cell dose required is unknown however a dose of 1-2 x 107 
NK cells/kg has been identified as the minimum safe dose to be used in combination 
with HSCT (Passweg et al., 2004) and even higher doses of 2 x 108 NK cells/kg have 
been shown to be well tolerated and non-toxic (Choi et al., 2014). Recent 
development in expansion methods from donor PB (Fujisaki et al., 2009b, Koehl et 
al., 2004, Escudier et al., 1994, Ishikawa et al., 2004), CB mononuclear cells (Shah 
et al., 2013) and differentiation from CBCD34+ cells (Spanholtz et al., 2010, 
Luevano et al., 2014) has overcome the hurdle of cell number. If NK cells could be 
cryopreserved prior to their requirement, NK cell therapy would then be accessible 
as an off-the-shelf therapy. From a practical perspective this would allow for 
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flexibility in planning and multiple infusions at different time points without needing 
to consider initial pharmacological treatment. 
 
Current studies on how cryopreservation effects NK cell function is limited and 
present literature suggests that the loss of function of PBNK cells post 
cryopreservation can only be rescued via IL-2 culture (Lapteva et al., 2012, 
Dominguez et al., 1997, Voshol et al., 1993, Holubova et al., 2016). An off-the-shelf 
cryopreserved NK cell product would be highly beneficial for clinical application as 
currently multiple infusions have shown the most consistent efficacy over in vivo 
expansion (Arai et al., 2008, Iliopoulou et al., 2010, Barkholt et al., 2009, Lundqvist 
et al., 2011, Ishikawa et al., 2004). Therefore, the aim of this chapter is to 
systematically assess which media and cell concentration is appropriate for 
cryopreservation of NK cells differentiated from CBCD34+ cells and how the 
freeze/thaw process effects their phenotype and function post cryopreservation.  
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5.2. Results 
 
5.2.1. Optimum freezing media for cryopreservation 
 
Initially it is required to identify what is the most suitable media for cryopreservation 
of NK cells. Several media can be used for cell cryopreservation and here we 
selected two types. These were selected as they contained the fewest reagents and 
therefore would be most economical for translation to the clinic. The first medium 
tested was AB serum and 10 % DMSO. FBS supplemented with 10 % DMSO is 
routinely used for freezing cells however due to its xenogeneic nature FBS cannot be 
considered for clinical use. AB serum and 10 % DMSO is currently the standard 
cryopreservation medium for clinical trials in immunotherapy (Best et al., 2007). 
Further, DMEM, 10 % AB serum and 10 % DMSO was also tested to assess whether 
a high concentration of AB serum was actually necessary. Using a lower 
concentration of AB serum would be beneficial due to its high cost and the potential 
presence of viruses, cytokines and growth factors that could skew immunological 
assessment. Further pooled batches are available in limited supply and therefore each 
new batch needs to be re-tested for suitability via a series of cellular assays 
(Germann et al., 2011). To identify which medium was optimal for cryopreservation 
of NK cells differentiated in vitro, percentage recovery and cytotoxicity of NK cells 
post-thaw was analysed. These parameters were focused on as percentage recovery 
shows that the cells can survive the cryopreservation and thawing process and 
cytotoxicity is the key function required for preventing relapse in a clinical setting. 
 
It was found that the level of cytotoxicity of NK cells differentiated in vitro was 
statistically equivalent whichever freezing media was used where DMEM, 10 % AB 
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serum and 10 % DMSO showed 23.35 % (19.39 - 27.3) specific lysis versus 20.46 % 
(13.64 - 27.28) with AB serum and 10 % DMSO, p = 0.6667 (figure 5.1A). 
Conversely, the percentage recovery of NK cells was better when using AB serum 
and 10 % DMSO 26.8 % (15.2 - 33.2) in comparison to 10.8 % (5.6 - 24) (figure 
5.1B), although this difference was not significant the rest of the study was continued 
using AB serum and 10 % DMSO. Even though there was no difference in 
cytotoxicity, percentage recovery was improved and therefore more cells were 
consistently obtained for functional and phenotypic analysis. 
 
Figure 5.1. The influence of cryopreservation media on CBCD34+-NK cell 
cytotoxicity and percentage recovery. A) 51Cr release assay was used to determine 
cytotoxicity, median specific K562 lysis (± range) by CBCD34+-NK cells frozen in 
AB serum and 10% DMSO (n = 2) and DMEM, 10% AB serum and 10 % DMSO (n 
= 2) is shown. B) Percentage recovery was analysed via cell count using trypan blue 
to exclude dead cells, percentage recovery = (number of viable cells/initial 
population frozen down) x 100. Median recovery (± range) of CBCD34+-NK cells 
post thaw by cells frozen in AB serum and 10 % DMSO (n = 3) and DMEM, 10 % 
AB serum and 10% DMSO (n = 3) is shown. 
 
5.2.2. Optimum cell concentration for cryopreservation 
 
Subsequently it was then important to assess whether freezing NK cells 
differentiated in vitro at different concentrations had an impact on cell recovery. It is 
necessary to identify the correct concentration for cryopreservation of NK cells as 
reduced availability of resources at high concentrations and lack of cellular cohesion 
at low concentrations can have a severe impact on cell survival. Classifying the most 
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suitable freezing concentration also allows the prediction of the cell numbers that can 
be recovered post thaw and therefore substantiate the cell numbers that need to be 
cryopreserved in order to obtain suitable cell doses for successful clinical 
application.  
 
Conventional laboratory protocols dictate that cryopreserving cells between the 
range of 106-107/mL are associated with improved survival, it was therefore decided 
that the cells would be frozen at 1 x 106 cells/mL and 5 x 106 cells/mL. 
Cryopreserving the cells at of 1 x 106 cells/mL seemed preferential as this resulted in 
an increased percentage recovery (44 % 16 - 88.2) however, this difference was not 
statistically significant to that obtained from 5 x 106 cells/mL (29 % 9.6 - 62) (figure 
5.2). Therefore, if the cost of reagents and freezing space is taken into consideration 
it can be concluded that 5 x 106 cells/mL is the most preferential freezing 
concentration.  
 
Figure 5.2. Percentage recovery of cryopreserved CBCD34+-NK cells post thaw. 
To determine percentage recovery cells were counted using trypan blue to remove 
dead cells. Percentage recovery = (number of viable cells/initial population frozen 
down) x 100. Median recovery (± range) of CBCD34+-NK cells post thaw by cells 
cryopreserved at 1 x 106/mL (n = 13) and 5 x 106/mL (n = 13) is shown. 
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5.2.3. Purity of NK cells post cryopreservation 
 
Even though there was no difference observed in the percentage recovery of the cells 
cryopreserved at either concentration it is necessary to confirm that there is no 
difference in purity or phenotype post-thaw as this could occur as a result of limited 
resources and ultimately stress induced upon the cells. 
 
NK cells are characterised as lymphocytes that are CD56+ and CD3- with CD56 
being the classical marker for NK cells while the inclusion of CD3 allows for the 
identification of NKT cell contaminants. Figure 5.3A shows a representative flow 
cytometry plot of the fresh and frozen NK cell populations as well as a graph of the 
percentage purity. These show that there is no difference in the purity of the cells 
post cryopreservation. Here the percentage purity of the fresh cells and those 
cryopreserved at 1 x 106/mL and 5 x 106/mL is 96.4 % (81.4 - 99.3), 97.7 % (70.8 -
99.2) and 97.2 % (77.9 - 99.0) respectively (figure 5.3B). 
 
 
 141 
 
Figure 5.3. Purity of cryopreserved CBCD34+-NK cells post thaw. A) 
Representative example of flow cytometric analysis of the CD56+CD3- populations 
of fresh CBCD34+-NK cells (n = 9) and frozen CBCD34+-NK cells cryopreserved at 
1 x 106/mL (n = 9) and 5 x 106/mL (n = 9). B) Purity of fresh CBCD34+-NK cells 
and frozen CBCD34+-NK cells cryopreserved at 1 x 106/mL and 5 x 106/mL. Median 
percentage (± range) of the live CD56+CD3- population is shown. 
 
5.2.4. Phenotype of NK cells post cryopreservation 
 
To further ensure that cryopreservation does not induce stress on NK cells and a 
resultant change in phenotype the expression of numerous markers required for NK 
cell cytotoxic function was assessed. NK cell function is finely controlled by a 
number of inhibitory and activating receptors. CD16 is a key-activating marker that 
is capable of inducing NK cell cytotoxic activity without synergy with other 
receptors (Bryceson et al., 2006b). CD69 is an early marker of NK cell activation. 
NKG2D and DNAM-1 can act as co-receptors or mediate killing directly whilst 
NKp30 and NKp46 are specific NCR where engagement leads to direct lysis of 
target cells (Moretta et al., 2002b). CD94 and NKG2A form a lectin-like complex 
that has an inhibitory impact on NK cell function (Voss et al., 1998, Screpanti et al., 
2005). Fas/Fas-L is a cell death pathway induced by ligand binding and this 
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interaction has been shown to correlate with tumour regression in vivo (Screpanti et 
al., 2005). Presence of perforin and granzyme B demonstrate a cell ability to engage 
in cytotoxicity, as perforin is able to perforate a target membrane whilst granzyme B 
induces programmed cell death. Figure 5.4A shows representative flow cytometry 
plots of receptor expression on NK cells. No statistically significant difference was 
observed between fresh and frozen NK cells, irrelevant of cell concentration at 
cryopreservation, by any of the receptors profiled (figure 5.4B). By assessing the 
level of expression of these receptors it can be confirmed that the cryopreservation 
process does not give rise to a cell subset distinct from fresh CBCD34+-NK cells. 
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Figure 5.4. Receptor analysis of cryopreserved CBCD34+-NK cells post thaw. A) 
Representative example of flow cytometric analysis showing expression of NK cell 
receptors by fresh CBCD34+-NK cells and frozen CBCD34+-NK cells cryopreserved 
at 1 x 106/mL and 5 x 106/mL. Histogram analysis was gated on the live CD56+CD3- 
population and positive population defined against negative control. B) Flow 
cytometry was used to determine surface antigen expression. After gating on the 
CD56+CD3- population median percentage (± range) expression for each receptor by 
fresh CBCD34+-NK cells (n = 12) and frozen CBCD34+-NK cells cryopreserved at 1 
x 106/mL (n = 12) and 5 x 106/mL (n = 12) is shown. 
 
5.2.5. Function post cryopreservation 
 
When assessing NK cell function of the freshly differentiated NK cells and how this 
compares post cryopreservation it is first important to analyse cytotoxicity of the 
cells, as this is a key function required to target malignancies and prevent relapse. By 
using a combination of both the Cr51 release assay and a flow cytometry based 
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method whilst comparing against healthy adult PB controls, the cytotoxic capacity of 
the cell can confidently be assessed. Figure 5.5 shows that there is no difference in 
the cytotoxic function of the cells whether assessed by Cr51 release or the flow 
cytometry methodology. This shows that cryopreservation has no impact on 
cytotoxicity of the CBCD34+-NK cells, irrelevant of concentration at freezing. 
Where the median specific lysis via the Cr51 release assays by the fresh CBCD34+-
NK cells was 22.53 % (17.42 - 39.19) in comparison to 17.7 % (6.70 - 28.44) for the 
cells cryopreserved at 1 x 106/mL and 11.11 % (4.34 - 32.71) for the cells 
cryopreserved at 5 x 106/mL. Further this work also demonstrates that the killing 
capacity of PBNK cell controls (11.65 % (8.71 - 12.12) is equivalent to the 
CBCD34+-NK cells. This inference is further supported by the flow cytometry based 
assay where no significance was observed between any of the groups and the level of 
cytotoxicity was equivalent. There is enhanced variability between PBNK cell 
samples however this is likely due to use of different donors for each of these assays. 
 
 
Figure 5.5. Cytotoxicity of cryopreserved CBCD34+-NK cells post thaw. 51Cr 
release assay (A) and a flow cytometry based assay (B) were used to assess cell 
cytotoxicity. The median specific lysis of K562 cells (± range) by fresh CBCD34+-
NK cells (n = 5), frozen CBCD34+-NK cells cryopreserved at 1 x 106/mL (n = 5) and 
5 x 106/mL (n = 5) and fresh PBNK cells (n = 3) is shown in both assays.  
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Figure 5.6 shows that the frozen cells can degranulate to the same degree as the fresh 
and PBNK controls when stimulated with K562 cells, where the frozen samples 
responded at 9.05 % (6.04 - 13.5) and 8.35 % (5.55 - 13) and the controls at 12.75 % 
(9.48 - 24.2) and 26 % (18.5 - 29.1) respectively. To identify the maximum 
degranulation potential of the cells PMA and Ionomycin stimulation was also carried 
out. This supported data seen with K562 cells and the same level of degranulation 
was observed where the frozen samples expressed CD107a at a level of 59.3 % (45.3 
- 66.0) and 61.6 % (46.9 - 67.8) and the fresh and PBNK positive controls expressed 
48.6 % (30.5 - 67.3) and 33 % (18.5 - 29.1). 
 
Figure 5.6. Degranulation of cryopreserved CBCD34+-NK cells post thaw. 
Surface CD107a were analysed by flow cytometry, median antigen expression (± 
range) by fresh CBCD34+-NK cells (n = 6), frozen CBCD34+-NK cells 
cryopreserved at 1 x 106/mL (n = 5) and 5 x 106/mL (n = 5) and fresh PBNK cells (n 
= 3) is shown. 
 
It is crucial to also consider if the cells can still proliferate post cryopreservation as if 
this cannot be achieved the NK cells will have little impact once infused in vivo. 
Proliferation was measured by CFSE analysis following stimulation of both IL-2 and 
IL-15. Fresh and frozen CBCD34+ NK cells and PBNK cells labeled with CFSE 
show the same pattern of proliferation between the different sources and this was 
irrelevant of the cytokine used (figure 5.7). The cryopreserved NK cells were capable 
of proliferating to the same degree as fresh NK cells differentiated in vitro as well as 
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the PBNK cell positive controls. 
 
Figure 5.7. Proliferation of cryopreserved CBCD34+-NK cells post thaw. CFSE 
analysis over a 7 day period after stimulation with IL-2 (A) and IL-15 (B) was used 
to assess cell proliferation, the median MFI of CFSE (± range) by fresh CBCD34+-
NK cells (n = 5), frozen CBCD34+-NK cells cryopreserved at 1 x 106/mL (n = 5) and 
5 x 106/mL (n = 5) and fresh PBNK cells (n = 5) is shown.  
 
Recognising that the cells are able to produce IFN- would further support that 
CBCD34+-NK cells are fully functional and are capable of producing a GvL effect. 
Here figure 5.8 shows no significant difference in the levels of intracellular IFN- 
between the fresh or frozen NK cells differentiated in vitro and PBNK cells. The 
frozen cells are capable of releasing the same level of IFN- when stimulated with 
K562 cells, where the cells frozen at 1 x 106 cells/mL release 9.19 % (4.5 - 13.1) and 
cells frozen at 5 x 10 6 cells/mL release 11.3 % (4.05 - 15.7). This is in comparison to 
the IFN- produced by the fresh and PBNK cell controls at 1.73 % (0.3 - 4.63) and 
3.93 % (2.29 - 4.29) respectively. This trend was further observed following 
stimulation with PMA and Ionomycin where the frozen cells preserved at 1 x 106 
cells/mL express 60.6 % (18.4 - 71.2) and those frozen at 5 x 106 cells/mL expressed 
56.3 % (18.2 - 72) compared to the fresh cells that express 21.8 % (4.75 - 38.9) and 
the PBNK cells at 66.0% (52.7 - 68.2 
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Figure 5.8. IFN- release of cryopreserved CBCD34+-NK cells post thaw. A) 
Representative FACS plot of intracellular IFN- B) Intracellular IFN- was detected 
by flow cytometry, median expression (± range) by fresh CBCD34+-NK cells (n = 
6), frozen CBCD34+-NK cells cryopreserved at 1 x 106/mL (n = 5) and 5 x 106/mL 
(n = 5) and fresh PBNK (n = 3) is shown. 
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5.3. Discussion 
 
NK cells are becoming an increasingly desirable product for clinical application 
however maintaining function post cryopreservation is a challenge that is being faced 
whatever the cell therapy considered. Achieving and optimising cryopreservation 
methodology is fundamental for the production of a desirable therapy for the clinic 
as it would allow the development of a readily available off-the-shelf product that 
could be infused at multiple time points. This in turn would be more economical as 
cells could be produced in large batches with limited waste. 
 
Here AB serum and 10 % DMSO was the cryopreservation media of choice however 
there are limitations associated with its use such as the high cost and presence of 
viruses, growth factors and cytokines which could effect the immunological response 
of the cells post thaw (Gstraunthaler, 2003). To overcome these limitations Best, et 
al 2007 (Best et al., 2007) have been optimising the use of a laboratory-developed 
substitute that is FDA approved known as plasmalyte-A. So far it has been shown 
that PBMC cell recovery is equivalent when compared to AB serum and 10 % 
DMSO however cellular function as demonstrated by CD3+ T cells was still affected. 
Work is now being carried out to optimise the use of plasmalyte-A as a basal 
medium for cryopreservation that could offer promise in the future for ensuring 
consistency of the final cell product. Further Mitchell and colleagues (Mitchell et al., 
2014) assessed the use of a serum free solution known as mFreSR for the 
cryopreservation of human embryonic stem cells (hESCs) in a quality by design 
concept. This integration of multiple process unit operations is an essential step in 
developing a cell based expansion process capable of meeting high batch sizes 
required for clinical application. Here optimisation of cryopreservation and 
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resuscitation was achieved resulting in enhanced viability and cell recovery post 
thaw. There are still significant cost implications using the mFreSR media however 
here it is shown that the concentration of NK cells at time of freezing does not 
impact on NK cell function, therefore a higher concentration can be considered for a 
more practical large-scale translation. Heathman (Heathman et al., 2015) also 
demonstrated in 2015 that MSCs could be processed, expanded and cryopreserved in 
a serum free system using a DMSO-free freezing media specific to MSCs called 
PRIME-XV. Post thaw, cell viability decreased to 75.8  1.4 % however, this value 
remains above the FDA guideline for cell-based therapies of 70 %. Further 
demonstrating that lymphocytes can be cryopreserved whilst maintaining function 
however optimisation of the whole cell processing method is necessary for the most 
successful results. 
 
Using current methodology a percentage recovery of 29 % was obtained. Although 
this may not be ideal for clinical application if it is considered that an average 
clinical grade CB unit contains 2.79  1.59 x 106 CD34+ cells (Spanholtz et al., 2011) 
and that 600 (Luevano et al., 2014) is the average fold expansion of the culture 
period where NK cells are differentiated from CBCD34+ cells then 1.67 x 109 NK 
cells could potentially be produced for clinical use. If recovery was maintained at 
this level it would still be possible to produce over 450 x 106 NK cells which would 
still allow for multiple infusions of the same NK cell product. In practical terms it is 
still necessary to improve percentage recovery and this could be achieved in the 
future by further optimising the cryopreservation media and using a controlled-rate 
freezer and bags for cryopreservation. 
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Previous literature suggests that cryopreservation of NK cells is not recommended as 
functionality and killing capacity is reduced post thaw. However one such studies 
used a concentration of 40% DMSO (Fujiwara et al., 1986) which has been reported 
as toxic to cells at such a high level (Fry et al., 2015), other works are in relation to 
resting PBNK cells or PBMCs (Voshol et al., 1993, Dominguez et al., 1997). Data on 
the clinical application of cryopreserved NK cells are limited, however Liu and 
colleagues (Liu et al., 2013) demonstrated that infusion of NK cells that were 
activated prior to cryopreservation, retained their anti-tumour function in a 
NOD/SCID mouse model of disseminated neuroblastoma. This supports the data 
here that clearly show that cryopreservation does not impact on function or 
phenotype of NK cells differentiated in vitro. Activation could therefore be an 
essential step prior to cryopreservation to maintain NK cell function and viability 
post thaw. 
 
Overall, it is shown here that NK cells differentiated from CBCD34+ cells can be 
cryopreserved and thawed whilst still maintaining function. This is a fundamental 
characteristic required to take this cell therapy to the clinic. 
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6.1. Current understanding 
 
The number of banked CB units is continuously growing. CB units are obtained via a 
non-invasive collection procedure and offer a rich source of CD34+ cells for the 
generation of highly functional NK cells. NK cells are capable of recognition and 
eradication of stressed and tumour cells. NK cell immunotherapy has the potential to 
utilise cytotoxicity against many different types of cancer as well as to enhance GvL 
in the context of HSCT. It has been shown that frozen CBCD34+ cells generate 
higher NK cell numbers without loss of function in comparison to fresh CBCD34+ 
cells and mPBCD34+ cells (Luevano et al., 2014) however in order to produce a 
successful clinical therapy further questions need to be answered. It is important to 
identify that the CBCD34+-NK cells are capable of further proliferation in order to 
expand once infused, they are functional in vivo and that they can target patient 
tumour cells. The aims of this thesis were to further characterise NK cells 
differentiated in vitro from CBCD34+ cells with the intention to translate the therapy 
to the clinic in the future. CBCD34+-NK cells exhibit a unique phenotype such as a 
low level of KIR expression but high level of activating receptors that could translate 
into a better killing of tumour cells over other NK cell sources. It is therefore 
important to further characterise the phenotype and function of these cells in order to 
clarify how their biology compares to PBNK cells and CBNK cells and elucidate if 
they could be an attractive source of NK cells for immunotherapy.  
 
In order to develop a successful clinical immunotherapy it is essential that NK cells 
are capable of expansion upon infusion to the patient in order to target malignancies. 
NK cells differentiated in vitro from CD34+ cells referred to throughout this work as 
CBCD34+-NK cells are capable of proliferation following additional cytokine 
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stimulation in vitro, suggesting that CBCD34+-NK cells may be able to expand 
further in vivo. CBCD34+-NK cells have longer telomeres and their expression of the 
NK cell maturation marker CD57 is significantly lower than PBNK cells and CBNK 
cells implying a less differentiated phenotype. However the cytotoxic effect in vivo 
against K562 cells and in vitro against numerous targets is unaffected. This 
demonstrates that killing capacity is uncompromised whether NK cells are 
differentiated in vitro or in vivo. In addition CBCD34+-NK cells are capable of 
proliferation, degranulation and cytotoxicity post cryopreservation to the same 
degree as their fresh counterparts and PBNK cells this allows for the development of 
an off-the-shelf NK cell therapy. 
 
6.2. CBCD34+-NK cells are superior to PBNK cells and CBNK cells 
 
Clinical trials have shown some positive data using NK cell immunotherapy however 
not all therapies have shown improvement on survival. This could be associated to 
the lack of NK cells with optimum activation status. This could be overcome by 
priming NK cells differentiated from CD34+ cells as overnight NK cell activation by 
priming has consistently been shown here to lead to significantly enhanced 
cytotoxicity against numerous NK cell resistant targets in comparison to overnight 
IL-2 activation. The CB CD34+ cells used to differentiate NK cells in vitro are 
collected by a non-invasive procedure from CB units that are not deemed suitable for 
transplantation. The use of CB cells could therefore maximise the use of clinical 
grade banked CB units. CBCD34+-NK cells have a less differentiated phenotype 
without loss of function and have previously been shown to persist for longer in vivo 
over other NK cell sources (Luevano et al., 2014), indicating an enhanced ability to 
survive for longer periods or proliferate more when used as a cell therapy in the 
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clinic. CBCD34+-NK cells have a lower expression of CD16 in comparison to other 
types of NK cells, whilst still being able to exert ADCC (Luevano 2014), however 
this is not shed after tumour priming which has been shown to occur with PBNK cell 
(Sabry et al., 2011). This could imply that CBCD34+-NK cells are less susceptible to 
the metalloprotease ADAM17 and its association with reduced NK cell function 
(Romee et al., 2013). It could therefore be suggested that CBCD34+-NK cells are a 
more desirable source of cells for NK immunotherapy over PBNK cells and CBNK 
cells.  
RNA sequencing that uses next generation technology to identify the presence and 
quantity of RNA present in a biological sample at a given moment could additionally 
shed light on differences with PBNK cells and CBNK cells in signaling molecules, 
receptors, proteins and transcription factors that could explain the different behaviour 
observed by primed CBCD34+-NK cells in vivo. Further, cytometry by time of flight 
(CyTOF) or fluidigm is a variation on flow cytometry that utilizes antibodies labeled 
with heavy metals instead of flurorochromes. This novel technique allows for the 
simultaneous identification of many more markers on one cell in comparison to 
conventional flow cytometry techniques. This further work could therefore provide 
further information supporting the use of CBCD34+-NK cells as a preferential source 
of NK cells for immunotherapy. A summary of key findings can be found in table 
6.1. 
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 CBCD34+-NK cells PBNK cells CBNK cells 
Proliferate in vitro    
EOMES/TBET expression Equivalent Equivalent Equivalent 
Telomere length  Longest Short Long 
CD57 Expression Lowest High Low 
Killing K562 cells in vivo  N/D N/D 
Killing AML cells in vitro    
Killing AML cells in vitro 
by primed NK cells 
   
Killing AML cells in vitro 
by IL-2 activated NK cells 
   
Killing AML cells in vivo  N/D N/D 
Killing solid tumours cells 
by resting NK cells 
3/7 1/7 1/7 
Killing solid tumours cells 
by primed NK cells 
   
Function post 
cryopreservation 
  
Table 6.1. Summary of key findings. N/D: not done 
 
6.3. Differentiation of memory-like NK cells 
 
It has been shown that cytokine stimulation is capable of inducing memory-like 
abilities in PBNK cells (Cooper et al., 2009a, Romee et al., 2012). Additionally it has 
been observed in a mouse model that adoptively transferred IL-12, 15 and 18 pre-
activated NK cells suppress GvHD in a fully mismatched HSCT setting (Huber et al., 
2015) and IL-12/15/18-induced memory-like NK cells expand and have an enhanced 
anti-AML function following adoptive transfer in patients (Romee et al., 2016). 
Therefore the possibility of differentiating memory-like NK cells in vitro is an 
exciting one. An effort was made to achieve this by stimulation of the cells with IL-
12, IL-15 and IL-18 at different time points of the culture and different 
concentrations of IL-15 maintenance. IFN- release and cytotoxicity against K562 
cells was assessed at multiple time points following this. Preliminary data showed 
that CBCD34+-NK cells have an enhanced production of IFN- following additional 
stimulation with inflammatory cytokines however the overall results were too 
variable deeming them inconclusive. This implies that the system may require further 
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modifications and optimisation, such as cell concentration at time of stimulation and 
cytokine addition, to successfully differentiate memory-like NK cells in vitro. 
Unfortunately due to time constraints this work could not be completed here. 
 
6.4. Translation to GMP 
 
It has been shown that it is possible to generate a GMP compliant NK cell product 
from CBCD34+ cells (Spanholtz et al., 2010, Spanholtz et al., 2011). These cells 
were used in a phase I clinical trial for patients not eligible for HSCT and were 
shown to reduce minimum residual disease in patients receiving hypomethylating 
agents (Dolstra et al., 2015). There could be correlations associated with NK cell 
dose and tumour eradication highlighting the importance of using high NK cell 
numbers with optimum activation status for clinical application. 
 
The first stage of clinical translation of a cell therapy is definition of the target 
product profile. Various guidelines have been established by regulatory agencies all 
over the world to ensure safe implementation of new therapies. The Medicines and 
Healthcare products Regulatory Agency (MHRA) is aligned to the European 
Medicines Agency (EMA) and are responsible for scientific evaluation of therapies 
in the UK and EU, any considerations must be taken into account before a therapy 
can be successfully translated to a clinical setting. 
 
The starting material to differentiate NK cells is CD34+ cells from CB. It is essential 
that the background information of each CB unit is well-documented, including 
quality control analysis of unit, definition of acceptance criteria, minimum total 
MNC count and viral safety. In this study CD34+ cells were isolated from whole CB 
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units prior to cryopreservation however optimal isolation of CD34+ cells from whole 
frozen CB units has previously been shown (Spanholtz et al., 2011). CD34+ 
isolations would also require a definition of purity; standard practice would be 2 
standard deviations below the respective analysis. The CB units utilised in this study 
were of a research standard with a lower mononuclear count and consequently 
CD34+ cell number. NK cell immunotherapy requires the use of high NK cell doses 
therefore the access to clinical grade units with higher CD34+ cell numbers will 
allow for the differentiation of higher NK cell numbers. 
 
Here a murine feeder layer was utilised to differentiate NK cells in vitro, cells were 
cultured at a fixed ratio of CD34+ cells to feeder cells of 1: 40 and feeder cells were 
always used after 2 passages from cryopreservation to confluence of a T-175 flask. 
The use of a xeno-feeder layer poses a large threat for clinical translation for a cell 
therapy due to the risk of viral contamination and xeno-toxicity. Although human 
cells lines have been approved for clinical expansion of Tregs and NK cells (Fujisaki 
et al., 2009b, Brunstein et al., 2016) the extensive further research, finance and time 
required to approve a feeder cell line for clinical application means it would be more 
favorable to transform the culture method to a feeder-free system. It has been 
previously shown that the NK cell differentiation protocol is a non-contact dependent 
system (Oostendorp 2011). Therefore the first transformation to a GMP compliant 
product could involve the complete removal of the feeder cells and culture of CD34+ 
cells in conditioning media and cytokine only. Following this, work could be carried 
identifying if microvesicles are involved as well as the analysis of the conditioning 
media content. A single study performed here identified that CD34+ cells cultured 
without a feeder layer differentiated much more rapidly indicating that maybe the 
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differentiation could successfully be achieved after adjustment of the cytokine 
cocktail. Additionally beads coated with molecules required for the differentiation of 
NK cells from CD34+ cells could be used if these molecules can be identified. 
 
Post culture acceptance criteria of the NK cell product it is also necessary. Purity can 
be defined as > 80 %, minimum viability of 70 %, endotoxin < 1.5 units and 
mycoplasma negative. NK cell killing of K562 cells at a fixed E : T ratio of 10: 1 in a 
4 h killing assay can be used to assess potency. It is difficult to identify a single 
threshold for potency due to lab-based variability. The assay should therefore be 
performed alongside PBNK cell positive controls, CBCD34+-NK cell function 
should then sit within 2 standard deviations of PBNK cell function. 
 
NK cell infusion should ideally take place after immunosuppressive regimen or after 
reduction of tumour mass in solid malignancies. In terms of HSCT NK cell infusion 
could take place on the day of or post-transplant though consideration that NK cells 
infused could be rejected by donor T cells must also be well-thought-out. 
Additionally a recent study showing that IL-15/4-1BBL activated NK cells resulted 
in the induction GvHD in a T cell depleted transplantation setting (Shah et al., 2015), 
which further calls into consideration how activated NK cell therapies should be 
applied. 
6.5. Animal studies 
 
It is essential that a cellular therapy is shown to be fully functional in vivo prior to 
clinical translation. Although a trend of reduced AML blasts in the BM of the mice 
injected with either resting or primed CBCD34+-NK cells is observed in the in vivo 
studies presented here this difference is not significant. This could be due to the short 
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assay length or hypopoxic environment of the BM that could suppress NK cell 
function (Spencer et al., 2014). In the future the assay could be repeated over a 
longer time point, for example 7 days, and function of the cells could be assessed in 
vitro after exposure to the BM niche. Further priming was not necessary to observe 
killing in vivo of patient AML blasts that could be the result of significantly reduced 
proliferation by primed CBCD34+-NK cells in comparison to cytokine stimulation. It 
could therefore be hypothesized that upon infusion into an irradiated mouse the 
cytokine storm could potentially activate the NK cells to proliferate significantly 
more than primed NK cells leading to better killing of tumour cells targeting. This 
could be tested in the future by infusing resting CBCD34+-NK cells into the mouse 
model and assessing the expression of markers associated with primed NK cells 
following dissection. Additionally blocking of pro-inflammatory cytokine receptors 
and assessment of NK cell cytotoxicity against NK cell resistant targets could 
indicate the involvement of a particular NK cell pathway. 
 
Interestingly it can also be seen here that primed NK cells of any source are 
significantly better at killing solid tumours in vitro over resting NK cells. Therefore 
in the future it would be of interest to identify if this enhanced cytotoxicity is 
observed in vivo. This will enable the identification of whether the difference of 
killing of AML blasts in vitro and in vivo is related to the type of cancer used or 
whether it applies regardless of the source of cancer cell.  
 
6.6. Future Directions 
 
Aside from the work mentioned previously CBCD34+-NK cells have the potential to 
be used in other fields of immunotherapy. Our group has previously shown that NK 
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cells can enhance HSC engraftment by increasing the clonogeneic capacity of CD34+ 
cells (Escobedo-Cousin 2015). NK cells do not target non-haematopoetic cells 
however very preliminary studies by a post-doctoral scientist in our lab observed 
lysis of CD34+ cells by allogeneic NK cells in vitro. Data testing the impact of 
allogeneic NK cells differentiated in vitro from CD34+ on CBCD34+ via CFU 
performed by myself interestingly demonstrated the differentiation of myeloid but 
not ethyroid (red blood cells/precursors) lineages not lysis of the whole CD34+ cell 
population. This could indicate that CD34+-NK cells have a reduced tendency to 
target non-self. HLA analysis of CBCD34+-NK cells alongside the co-cultured 
CD34+ cells could identify a mismatch that may be equivalent to that required for 
CBT that will enhance the clonogenic capacity of CD34+ cells whilst still 
maintaining a GvL effect without causing GvHD. This could then be applied to 
HSCT with a T cell deplete graft that won’t have associated relapse or rejection. KIR 
mismatch has previously been attributed to GvL effect but KIR expression on NK 
cells differentiated in vitro is low however CBCD34+-NK cells are still mature and 
do not demonstrate anergy. Here only KIR2DL1, KIR2DS1, KIR2DS3 and 
KIR2DS5 were profiled for therefore a thorough analysis of the KIR markers 
expressed by CBCD34+-NK cells using cell based and molecular based 
methodologies would benefit this work and may identify what level of mismatch if 
any is associated with CD34+ lysis and what could be tolerated leading to enhanced 
clonogeneic capacity. Alloreactivity according to ligand mismatch could be tested 
prior to banking in order to select the best cell product to accompany HSCT. Patients 
could then receive single or multiple infusions of a personalised cell therapy with the 
possibility of less stringent HLA-matching.  
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